

SUPPLEMENTARY INFORMATION

Supplementary tables and table legends 1-5

Supplementary figures 1 (raw gel data) and 2 (FACS gating strategies for immune cell analysis)

Raw data (weight monitoring over disease time course) of *in vivo* experiment (oxazolone colitis)

Total organic synthesis of BfaGC analogue (SB2201-SB2223) library

Name	Molecular Weight	Sphingosine Structure	Fatty Acyl Structure	MS2 Fingerprint	Retention Time
SB2201	717.58	n18	3-OH-n16	504	8.47
SB2202	703.56	n18	3-OH-n15	504	8.05
SB2203	731.59	n18	3-OH-i17	504	8.72
SB2204	731.59	n18	3-OH-a17	504	8.72
SB2205	731.59	n19	3-OH-n16	518	8.84
SB2206	717.58	n19	3-OH-n15	518	8.45
SB2207	745.61	n19	3-OH-i17	518	9.08
SB2208	745.61	n19	3-OH-a17	518	9.06
SB2209	703.56	i17	3-OH-n16	490	7.92
SB2210	689.54	i17	3-OH-n15	490	7.40
SB2211	717.58	i17	3-OH-i17	490	8.24
SB2212	717.58	i17	3-OH-a17	490	8.23
SB2213	703.56	a17	3-OH-n16	490	7.87
SB2214	689.54	a17	3-OH-n15	490	7.35
SB2215	717.58	a17	3-OH-i17	490	8.23
SB2216	717.58	a17	3-OH-a17	490	8.20
SB2217	717.58	i17	3-OH-n17	490	8.33
SB2218	717.58	a17	3-OH-n17	490	8.33
SB2219	717.58	n17	3-OH-n17	490	8.42
SB2220	717.58	n17	3-OH-i17	490	8.35
SB2221	717.58	n17	3-OH-a17	490	8.33
SB2222	701.58	i17	n17	538*	8.91
SB2223	703.56	n16	3-OH-n17	476	8.06

n	straight-chain
i	Isomethyl (omega-2)-branching
a	Ante-isomethyl (omega-3)-branching

*does not have acyl 3-OH: fingerprint ion is [M-H-162]

Supplementary Table 1. Molecular weight and sphingolipid structure information for 23 synthetic BfaGCs.

Name	Sequence
pNJR6_3671_L-F	AAC GAA AAA TTT AAA CAA ATT ATT AAT CAG AGT CTG TAT TGG CTG CCC T
pNJR6_3671-L-R	ATC GAA CGT ATC GTT AGT TAT TAG TTA TTT TCG ATT GAG C
pNJR6_3671-Rg-F	CTA ATA ACT AAC GAT ACG TTC GAT AAA TGA ACT ACA AAA TAA CAA CCC
pNJR6_3671-Rg-R	CGG ATC CCC GGG TAC TCG CCA CGT CCG CAA CCC
3671-500F (1F)	GAC GCT TCG CCT CAG AAA C
3671+1520R (1R)	TTC AAA AGT ATC GGG ACG CAT C
pNBU2-3671F (2F)	AAA GAC ATA TAA AAG AAA AGA CAC CAT GAA AGA AAT AGA CTG GGC TAA TCT G
pNBU2-3671R (2R)	CAC TGG AAG ATA GGC AAT TAG TTA TTC AAC AAT AGT CAC CCA TCC G

Name	Sequence
Leu-3	CAC TTG ACT GTT GTA GAT AAA GC
Leu-4	CAT CTT CAT TGC AGC ATT ATC C
BACT1369F	CGG TGA ATA CGT TCY CGG
PROK1492R	GGW TAC CTT GTT ACG ACT T

Supplementary Table 2. Primer sequences used for the *B. fragilis* KO generation (top) and abundance analysis in HMB stool samples by qPCR (bottom).

	2C12 TCR-mCD1d- SB2217	2C12 TCR-mCD1d- SB2219
Data collection		
Temperature	100K	100K
Resolution limits (Å)	76.79-2.4 (2.5-2.4)	48.56-2.8 (2.9-2.8)
Space Group	P2 ₁ 2 ₁ 2 ₁	P2 ₁ 2 ₁ 2 ₁
Cell dimensions (Å)	a=58.5, b=80.9, c=243.3 $\alpha=\beta=\gamma=90^\circ$	a=58.3, b=80.6, c=242.8 $\alpha=\beta=\gamma=90^\circ$
Total N ^o . observations	299101 (44393)	267870 (36163)
N ^o . unique observations	46370 (6678)	29106 (4070)
Multiplicity	6.5 (6.6)	9.2 (8.9)
Data completeness	100 (100)	99.2 (97)
Wilson B-factors (Å ²)	62.1	82.7
I/ σ ₁	7.2 (1.9)	10.8 (2.1)
R _{p.i.m} ¹ (%)	5.5 (36.6)	4.2 (28.3)
Refinement statistics		
R _{factor} ² (%)	18.4	20.1
R _{free} ³ (%)	23	27.4
Non-hydrogen atoms		
- Protein	6530	6542
- Water	226	152
- Heterogen	152	155
Ramachandran plot (%)		
- Allowed region	99.52	99.52
- Disallowed region	0.48	0.48
rmsd bonds (Å)	0.010	0.008
rmsd angles (°)	1.15	1.03

$$^1 R_{p.i.m} = \frac{\sum_{hkl} [1/(N-1)]^{1/2} \sum_i |I_{hkl, i} - \langle I_{hkl} \rangle|}{\sum_{hkl} \langle I_{hkl} \rangle}$$

$$^2 R_{factor} = \frac{(\sum | |F_o| - |F_c| |)}{(\sum |F_o|)} - \text{for all data except as indicated in footnote 3.}$$

³ 5% of data was used for the R_{free} calculation.

Values in the parentheses refer to the highest resolution shell.

Supplementary Table 3. Data collection and refinement statistics of X-ray crystallography study.

TCR gene	TCR residues	CD1d residues	Bond type
CDR3 α	Asp94-O δ 1	Arg79-N η 2	HB
CDR3 α	Asp94-O δ 2	Arg79-N η 1	HB
CDR3 α	Asp94	Arg79	VDW
CDR3 α	Arg95-N ϵ	Asp80-O δ 1, Asp80-O δ 2	HB
CDR3 α	Arg95-N η 1	Arg79-N ϵ	HB
CDR3 α	Arg95-N η 2	Arg79-N η 2	HB
CDR3 α	Arg95	Ser76, Arg79, Asp80	VDW
CDR3 α	Gly96-O	Ala152-O	HB
CDR3 α	Gly96	Ala152, Asp153	VDW
CDR3 α	Ser97	Arg79, Val149, Ala152, Asp153	VDW
CDR3 α	Leu99-O	Arg79-N η 2	HB
CDR3 α	Leu99	Asp80, Leu84, Met87, Val149	VDW
CDR3 α	Gly100	Arg79	VDW
CDR3 α	Arg103	Arg79, Glu83	VDW
CDR2 β	Tyr48-O η	Glu83-O ϵ 2	HB
CDR2 β	Tyr48	Glu83, Lys86	VDW
CDR2 β	Tyr50-O η	Glu83-O ϵ 2	HB
CDR2 β	Tyr50	Glu83, Met87, Lys86	VDW
CDR2 β	Glu56	Lys86	VDW
CDR3 β	Glu97-O δ 2	Lys148-N ζ	HB
CDR3 β	Glu97	Ala152, Lys148	VDW
TCR gene	TCR residues	SB2217 atoms	Bond type
CDR1 α	Pro28	C1, O5"	VDW
CDR1 α	Asn30-N δ 2	3"-OH	HB
CDR1 α	Asn30	4"-OH, C3, 3"-OH	VDW
CDR3 α	Arg95	C1, C2, 2"-OH, O3	VDW
CDR3 α	Gly96-N	2"-OH	HB
CDR3 α	Gly96	C2, 3"-OH	VDW

HB: Hydrogen bond, VDW: van der Waals, Cut-off at 4 Å for VDW interactions and 3.5 Å for HB.

Supplementary Table 4. 2C12 TCR contacts with SB2217 and mCD1d.

TCR gene	TCR residues	CD1d residues	Bond type
CDR1 α	Thr27	Val72	VDW
CDR1 α	Pro28	Ser76	VDW
CDR3 α	Asp94-O δ 1	Arg79-N η 1, N η 2	HB
CDR3 α	Asp94	Arg79	VDW
CDR3 α	Arg95-N ϵ	Asp80-O δ 1	HB
CDR3 α	Arg95	Ser76, Arg79, Asp80	VDW
CDR3 α	Gly96-O	Ala152-O	HB
CDR3 α	Gly96	Ala152, Asp153	VDW
CDR3 α	Ser97	Val149, Ala152	VDW
CDR3 α	Leu99-O	Arg79-N η 2	HB
CDR3 α	Leu99	Asp80, Glu83, Leu84, Met87, Val149	VDW
CDR3 α	Gly100	Arg79	VDW
CDR3 α	Arg101	Arg79, Glu83	VDW
CDR2 β	Tyr48-O η	Glu83-O ϵ 1, Glu83-O ϵ 2, Lys86-N ζ	HB
CDR2 β	Tyr48	Glu83, Lys86	VDW
CDR2 β	Tyr50-O η	Glu83-O ϵ 2	HB
CDR2 β	Tyr50	Glu83, Met87	VDW
CDR2 β	Glu56-O ϵ 1	Arg21-N η 1	HB
CDR2 β	Glu56	Lys86	VDW
CDR3 β	Glu96	Lys148, Val149, Ala152	VDW
TCR gene	TCR residues	SB2219 atoms	Bond type
CDR1 α	Pro28	O5", C6, C1	VDW
CDR1 α	Asn30-N δ 2	3"-OH	HB
CDR1 α	Asn30	C3, 4"-OH, C2, 3"-OH	VDW
CDR1 α	Asn30-N δ 2	4"-OH	HB
CDR3 α	Asp94, Arg95	C1	VDW
CDR3 α	Arg95, Gly96	C2, 3"-OH	VDW
CDR3 α	Gly96-N	2"-OH	HB
CDR3 α	Arg95	C1, O1, O3, 2"-OH	VDW

HB: Hydrogen bond, VDW: van der Waals, Cut-off at 4 Å for VDW interactions and 3.5 Å for HB.


Supplementary table 5. 2C12 TCR contacts with SB2219 and mCD1d.



Supplementary Figure 1. Raw gel image for Extended figure 8A.


A

colonic NKT



B

splenic DC



Supplementary Figure 2. Gating and sorting strategies of (A) colonic NKT cells and (B) splenic DCs.

Day after challenge	Vehicle					
	0	100	100	100	100	100
1	93.5115	82.963	94.9807	89.1975	89.5604	86.6883
2	88.5496	81.4815	99.2278	84.8765	81.8681	80.1948
3	deceased	80	98.4556	83.0247	78.022	82.7922


SB2217						
	100	100	100	100	100	100
	99.5851	98.8372	96.9231	93.5211	94.2197	102.907
	105.3942	101.1628	100.3846	89.8592	94.2197	103.7791
	108.7137	106.2016	101.9231	87.8873	98.8439	103.7791

All data are weight(%) based on day 0 measurement of individual animal as 100%.

Supplemental Material for Oh *et al.* : Synthesis of BfaGC analog library

A. Synthesis of carboxylic acid building blocks


For the preparation of acyl building blocks, we first synthesized C₁₃ alkyl iodide having diol at 1,3 position (**S12**) from L-(–)-malic acid. Then we obtained acyl building blocks (**S14**{*n*17}–**S14**{*n*16}) as a carboxylic acid form after the introduction of various normal and branch structure via sp³–sp³ cross-coupling followed by oxidation.



Synthesis of **S2**, (S)-butane-1,2,4-triol

To a solution of boron dimethyl sulfide complex (157 mmol) and trimethyl borate (269 mmol) in dry THF (70 mL) under Ar(g) was added **S1** (L-(–)-malic acid, 44.8 mmol) in dry THF (20 mL) dropwise for 1 hr at water bath, then the reaction mixture was stirred at 35 °C for overnight. After the completion of the reaction monitored by TLC, the reaction was quenched by slow adding of MeOH (10 mL) at water bath and stirred for additional 4 hr at room temperature (r.t.). Solvent was evaporated under reduced pressure and azeotroped with MeOH 3 times. The residue was purified by silica-gel flash column chromatography (MeOH:DCM = 1:10 to 1:6 gradient elution) to provide the desired product (41.0 mmol, 91.6%). LRMS(ESI) *m/z* for C₄H₁₁O₃ [M + H]⁺ calcd: 107.06, found: 107.10.

Synthesis of **S3a**, **S3b**, and **S4**, (S)-2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethan-1-ol, (S)-(2,2-dimethyl-1,3-dioxan-4-yl)methanol, and (S)-4-(2-((4-methoxybenzyl)oxy)ethyl)-2,2-dimethyl-1,3-dioxolane




To a solution of **S2** (63.8 mmol) in acetone (300 mL) were added 2,2-dimethoxypropane (191.3 mmol), pyridinium-*p*-toluene sulfonate (5.10 mmol), then the reaction mixture was stirred at 70 °C (reflux) for overnight. After the completion of the reaction


monitored by TLC, solvent was evaporated under reduced pressure and the resultant was purified by silica-gel flash column chromatography (EtOAc:Hex = 1:2 to 1.5:1 gradient elution) to provide the inseparable mixture of 5-membered and 6-membered as 9:1 ratio (45.5 mmol, 71%).

To a solution of NaH (8.89 mmol) in dry THF (60 mL) under Ar(g) was added resulting inseparable mixture (**S3a** and **S3b**, 6.84 mmol) at 0 °C slowly and the reaction mixture was stirred for 30 min at r.t. *p*-Methoxybenzyl chloride (8.89 mmol), tetrabutylammonium iodide (0.889 mmol) were added to the reaction mixture, then the reaction mixture was stirred at 60 °C for overnight. After the completion of reaction monitored by TLC, the reaction mixture was diluted with EtOAc (100 mL) and washed with brine. Resulting organic layer was dried over anhydrous Na₂SO₄(s) and solvent was evaporated under reduced pressure. The residue was purified by silica-gel flash column chromatography (EtOAc:Hex = 1:15 to 1:5 gradient elution) to provide the desired product (1.55 g, 85%). ¹H NMR (300 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.25 (d, *J* = 8.1, Hz, 2H), 6.87 (d, *J* = 8.7, Hz, 2H), 4.43 (s, 2H), 4.20 (quin, *J* = 6.6 Hz, 1H), 4.05 (dd, *J* = 8.1, 6.0 Hz, 1H), 3.80 (s, 3H), 3.59–3.51 (m, 3H), 1.96–1.79 (m, 2H), 1.34 (s, 3H), 1.35 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 159.4, 130.6, 129.4, 114.0, 108.7, 74.1, 73.0, 70.0, 67.0, 55.5, 34.1, 27.1, 26.0; LRMS(ESI) *m/z* for C₇H₁₅O₃ [M + H]⁺ calcd: 147.09, found: 147.10.

Synthesis of **S5**, (S)-4-((4-methoxybenzyl)oxy)butane-1,2-diol



To a solution of **S4** (14.1 mmol) in MeOH (100 mL) was added pyridinium-*p*-toluenesulfonate (1.41 mmol) and the reaction mixture was stirred at r.t. for 18 hr. Solvent was evaporated under reduced pressure and the residue was purified by silica-gel flash column chromatography (MeOH:DCM = 1:40 to 1:18 gradient elution) to provide the desired product (2.99 g, 93%). ¹H NMR (400 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.25 (d, *J* = 8.4 Hz, 2H), 6.88 (d, *J* = 8.4 Hz, 2H), 4.46 (s, 2H), 3.90 (m, 1H), 3.81 (s, 3H), 3.69–3.60 (m, 3H), 3.49 (dd, *J* = 11.4, 6.2 Hz, 1H), 1.87–1.78 (m, 1H), 1.75–1.68 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 159.5, 130.0, 129.6, 114.1, 73.2, 71.6, 68.2, 66.8, 55.5, 33.0, 14.4; LRMS(ESI) *m/z* for C₁₂H₁₈NaO₄ [M + Na]⁺ calcd: 249.11, found: 249.05.

Synthesis of **S6** and **S7**, (S)-2-hydroxy-4-((4-methoxybenzyl)oxy)butyl methanesulfonate and (S)-2-(2-((4-methoxybenzyl)oxy)ethyl)oxirane




To a solution of **S5** (5.46 mmol) and collidine (54.6 mmol) in dry DCM (100 mL) was added methanesulfonyl chloride (6.56 mmol) dropwise over 1 hr under Ar(g) at 0 °C and the reaction mixture was stirred for 12 hr. Then, the reaction mixture was diluted with DCM (100 mL) and washed with brine. Organic layer was dried over anhydrous Na₂SO₄(s) and solvent was evaporated under reduced pressure. Then, to a solution of **S6** in dry diethylether (60 mL) was added tetrabutylammonium hydroxide (1M solution in MeOH, 7.10 mmol) under Ar(g) at 0 °C slowly. The reaction mixture was stirred at 0 °C for 6 hr. After the completion of the reaction monitored by TLC, the reaction mixture was diluted with EtOAc (100 mL) and washed with NH₄Cl(aq.) and organic layer was dried over anhydrous Na₂SO₄(s) and solvent was evaporated under reduced pressure. The residue was purified by silica-gel flash column chromatography (EtOAc:Hex = 1:10 to 1:5 gradient elution) to provide the desired product (932 mg, 82% as 2 step yield). ¹H NMR (500 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.26 (d, *J* = 8.0 Hz, 2H), 6.88 (d, *J* = 8.5 Hz, 2H), 4.46 (s, 2H), 3.80 (s, 3H), 3.61–3.57 (m, 2H), 3.07–3.04 (m, 1H), 2.78 (t, *J* = 4.5 Hz, 1H), 2.52 (dd, *J* = 4.5, 3.0 Hz, 1H), 1.92–1.87 (m, 1H), 1.80–1.73 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 159.4, 129.5, 127.2, 114.0, 73.0, 66.9, 55.5, 50.3, 47.3, 33.2; LRMS(ESI) *m/z* for C₁₂H₁₆NaO₃ [M + Na]⁺ calcd: 231.10, found: 231.00.

Synthesis of **S9**, (3R)-1-((4-methoxybenzyl)oxy)-13-(((tetrahydro-2H-pyran-2-yl)oxy)tridec-5-yn-3-ol




To a solution of **S8** (non-8-ynoxycyclohexane, 15.6 mmol) in dry THF was added *n*-butyllithium (17.6 mmol) under Ar(g) at -78 °C slowly and reaction mixture was stirred for 15 min at -78 °C. **S7** (13.5 mmol), boron trifluoride diethyl etherate (14.9 mmol) in dry THF were added to the reaction mixture at -78 °C slowly and the reaction mixture was stirred at ambient temperature. After the completion of the reaction monitored by TLC, the reaction mixture was diluted with EtOAc (100 mL) and washed with NH₄Cl (aq.) and organic layer was dried over anhydrous Na₂SO₄(s). Solvent was evaporated under reduced pressure and the residue was purified by silica-gel flash column chromatography (EtOAc:Hex = 1:10 to 1:3 gradient elution) to provide the desired product (4.79 g, 82%). ¹H NMR (300 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.25 (d, *J* = 14.0 Hz, 2H), 6.87 (d, *J* = 14.5 Hz, 2H), 4.57 (t, *J* = 6.0 Hz, 1H), 4.45 (s, 2H), 3.87–3.82 (m, 1H), 3.80 (s, 4H), 3.76–3.60 (m, 3H), 3.53–3.48 (m, 1H), 3.41–3.34 (m, 1H), 2.98 (d, *J* = 6.0 Hz, 1H), 2.36–2.34 (m, 2H), 2.17–2.11 (m, 2H), 2.04–1.99 (m, 1H), 1.89–1.79 (m, 3H), 1.61–1.43 (m, 6H), 1.37–1.08 (m, 8H); LRMS(ESI) *m/z* for C₂₆H₄₀NaO₅ [M + Na]⁺ calcd: 455.28, found: 455.20.

Synthesis of **S10**, (3R,*Z*)-1-((4-methoxybenzyl)oxy)-13-(((tetrahydro-2H-pyran-2-yl)oxy)tridec-5-en-3-ol




To a solution of **S9** (7.40 mmol) in EtOH/DCM (3:1, v/v) was added Lindlar catalyst (450 mg, 20 wt%) and the reaction mixture was stirred under H₂(g) at r.t. for 8 hr. After the completion of the reaction monitored by TLC, the reaction mixture was filtered through celite and solvent was evaporated under reduced pressure to provide the desired product (3.14 g, 98%). ¹H NMR (400 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.25 (d, *J* = 8.4 Hz, 2H), 6.87 (d, *J* = 8.4 Hz, 2H), 5.54–5.44 (m, 1H), 5.41–5.36 (m, 1H), 4.57 (t, *J* = 4.4 Hz, 1H), 4.45 (s, 2H), 3.90–3.80 (m, 1H), 3.78 (s, 4H), 3.76–3.66 (m, 2H), 3.64–3.58 (m, 1H), 3.52–3.47 (m, 1H), 3.40–3.35 (m, 1H), 2.89 (t, *J* = 3.0 Hz, 1H), 2.30–2.15 (m, 2H), 2.05–1.97 (m, 1H), 1.86–1.78 (m, 1H), 1.77–1.66 (m, 3H), 1.62–1.49 (m, 6H), 1.38–1.26 (m, 8H); LRMS(ESI) *m/z* for C₂₆H₄₂NaO₅ [M + Na]⁺ calcd: 457.29, found: 457.20.

Synthesis of **S11**, 2-(((R,*Z*)-11-(benzyloxy)-13-(((4-methoxybenzyl)oxy)tridec-8-en-1-yl)oxy)tetrahydro-2H-pyran



To a solution of NaH (5.06 mmol) in dry DMF (40 mL) was added **S10** (3.89 mmol) under Ar(g) slowly at 0 °C. After stirring at 0 °C for 1 hr, benzyl chloride (5.06 mmol), tetrabutylammonium iodide (1.01 mmol) were added to the reaction mixture. Then, the reaction mixture was stirred at 60 °C for overnight. After the completion of the reaction monitored by TLC, reaction was quenched by adding NH₄Cl (aq.) (40 mL) at water bath. Organic layer was extracted with EtOAc (20 mL × 3) and dried over anhydrous Na₂SO₄(s) and solvent was evaporated under reduced pressure. The residue was purified by silica-gel flash column chromatography (EtOAc:Hex = 1:12 to 1:3 gradient elution) to provide the desired product (875 mg, 43%). ¹H NMR (400 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.34–7.23 (m, 7H), 6.86 (d, *J* = 8.4 Hz, 2H), 5.50–5.39 (m, 2H), 4.60–4.56 (m, 2H), 4.45–4.36 (m, 3H), 3.87 (dt, *J* = 7.6, 2.8 Hz, 1H), 3.79 (s, 3H), 3.73 (q, *J* = 6.8 Hz, 1H), 3.64–3.47 (m, 4H), 3.41–3.35 (m, 1H), 2.39–2.25 (m, 2H), 1.86–1.77 (m, 2H), 1.74–1.68 (m, 1H), 1.61–1.50 (m, 9H), 1.36–1.25 (m, 15H); LRMS(ESI) *m/z* for C₃₃H₄₈NaO₅ [M + Na]⁺ calcd: 547.34, found: 547.30.

Synthesis of **S12**, (R,Z)-1-(((3-(benzyloxy)-13-iodotridec-5-en-1-yl)oxy)methyl)-4-methoxybenzene



Pyridinium-*p*-toluenesulfonate (0.431 mmol) was added to a solution of **S11** (4.31 mmol) in MeOH (30 mL) and the reaction mixture was stirred at r.t. for overnight. After the completion of the reaction monitored by TLC, solvent was evaporated under reduced pressure. The residue was purified by silica-gel flash column chromatography (EtOAc:Hex = 1:5 to 1:2.5 gradient elution) to give the hydroxy product (1.90 g, quantitative). ¹H NMR (300 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.34–7.22 (m, 7H), 6.86 (d, *J* = 8.4 Hz, 2H), 5.56–5.38 (m, 2H), 4.58 (dd, *J* = 11.7, 3.3 Hz, 1H), 4.49–4.44 (m, 1H), 4.41–4.35 (m, 2H), 3.79 (s, 3H), 3.64–3.51 (m, 5H), 2.35–2.24 (m, 2H), 2.04–1.96 (m, 2H), 1.84–1.77 (m, 2H), 1.58–1.50 (m, 2H), 1.37–1.23 (m, 10H); LRMS(ESI) *m/z* for C₂₈H₄₁O₄ [M + H]⁺ calcd: 441.29, found: 441.25.

OH-S11 (4.31 mmol) and methanesulfonyl chloride (6.46 mmol) were dissolved in dry THF under Ar(g), then dry triethylamine (8.61 mmol) was added to the reaction mixture. After stirring at r.t. for 4 hr, solvent was evaporated under reduced pressure and the residue was purified by silica-gel flash column chromatography (EtOAc:Hex = 1:5 to 1:2.5 gradient elution) to give mesylated product (2.21 g, 99%). ¹H NMR (400 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.34–7.23 (m, 7H), 6.86 (d, *J* = 8.4 Hz, 2H), 5.49–5.38 (m, 2H), 4.54 (ddd, *J* = 28.0, 11.2, 4.0 Hz, 1H), 4.45–4.36 (m, 3H), 4.20 (t, *J* = 6.4 Hz, 2H), 3.79 (s, 3H), 3.64–3.50 (m, 3H), 2.98 (s, 3H), 2.37–2.26 (m, 2H), 2.04–2.96 (m, 2H), 1.85–1.77 (m, 2H), 1.76–1.69 (m, 2H), 1.41–1.25 (m, 10H); LRMS(ESI) *m/z* for C₂₉H₄₃O₆S [M + H]⁺ calcd: 519.27, found: 519.20.


O-mesylated S11 (4.24 mmol), sodium iodide (3.86 g) and sodium carbonate (41.6 mg) were dissolved in acetone and the reaction mixture was stirred at reflux. After the completion of the reaction monitored by TLC, the reaction mixture was condensed under reduced pressure and the residue was purified by silica-gel flash column chromatography (EtOAc:Hex = 1:20 to 1:7 gradient elution) to give iodinated product (2.19 g, 94%). ¹H NMR (400 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.34–7.12 (m, 7H), 6.86 (d, *J* = 8.4 Hz, 2H), 5.49–5.38 (m, 2H), 4.54 (ddd, *J* = 28.0, 12.0, 4.4 Hz, 1H), 4.45–4.39 (m, 3H), 3.79 (s, 3H), 3.64–3.50 (m, 3H), 3.17 (quin, *J* = 4.6 Hz, 2H), 2.38–2.25 (m, 2H), 2.04–1.96 (m, 2H), 1.85–1.74 (m, 4H), 1.39–1.23 (m, 8H); LRMS(ESI) *m/z* for C₂₈H₄₀I₂O₃ [M + H]⁺ calcd: 573.18, found: 573.10.

General procedure of the Cu^(I)-mediated sp³-sp³ cross coupling




To a solution of **S12** (1.0 equiv.) in dry THF (0.1 M for **S12**) were added alkylmagnesium halide (4.0 equiv.) and dilithium tetrachlorocuprate (0.4 equiv.) successively at 0 °C. The reaction mixture was stirred at 0 °C for overnight. After the completion of the reaction monitored by TLC, the reaction was quenched by adding NH₄Cl(aq.) and organic layer was extracted with EtOAc (30 mL × 3) and dried over anhydrous Na₂SO₄(s). The resultant was condensed under reduced pressure and the residue was purified by silica-gel flash column chromatography (EtOAc:Hex = 1:25 to 1:12 gradient elution) to provide the desired product.

Synthesis of S13{n15}, (R,Z)-1-(((3-(benzyloxy)pentadec-5-en-1-yl)oxy)methyl)-4-methoxybenzene




Yield: 79%; ¹H NMR (400 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.34–7.23 (m, 7H), 6.86 (d, *J* = 8.8 Hz, 2H), 5.51–5.39 (m, 2H), 4.59 (d, *J* = 11.2 Hz, 1H), 4.45–4.36 (m, 3H), 3.79 (s, 3H), 3.66–3.50 (m, 3H), 2.38–2.27 (m, 2H), 2.02 (q, *J* = 6.4 Hz, 2H), 1.86–1.78 (m, 2H), 1.32–1.26 (m, 12H), 0.88 (t, *J* = 6.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 159.3, 139.1, 132.4, 130.9, 129.5, 128.5, 128.0, 127.7, 125.2, 113.9, 76.3, 72.8, 71.5, 71.4, 66.9, 55.5, 34.7, 32.1, 32.1, 29.8, 29.8, 29.6, 29.5, 29.4, 27.7, 22.9, 14.3; LRMS(ESI) *m/z* for C₃₀H₄₄NaO₃ [M + Na]⁺ calcd: 475.32, found: 475.25.

Synthesis of S13{n16}, (R,Z)-1-(((3-(benzyloxy)hexadec-5-en-1-yl)oxy)methyl)-4-methoxybenzene




Yield: 48%; ¹H NMR (300 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.35–7.21 (m, 7H), 6.86 (d, *J* = 8.7 Hz, 2H), 5.52–5.37 (m, 2H), 4.59 (d, *J* = 11.4 Hz, 1H), 4.45–4.35 (m, 3H), 3.79 (s, 3H), 3.67–3.51 (m, 3H), 2.38–2.24 (m, 2H), 2.02 (q, *J* = 6.6 Hz, 2H), 1.85–1.76 (m, 2H), 1.26 (m, 14H), 0.88 (t, *J* = 6.6 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 159.1, 138.9, 132.2, 130.7, 129.3, 128.3, 127.8, 127.5, 125.0, 113.8, 76.1, 72.6, 71.3, 66.7, 55.3, 34.5, 31.9, 31.9, 29.7, 29.6, 29.4, 29.3, 27.5, 22.7, 14.1; LRMS(ESI) *m/z* for C₃₁H₄₆NaO₃ [M + Na]⁺ calcd: 489.33, found: 489.30.

Synthesis of S13{n17}, (R,Z)-1-(((3-(benzyloxy)heptadec-5-en-1-yl)oxy)methyl)-4-methoxybenzene




Yield: 68%; ¹H NMR (400 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.33–7.22 (m, 7H), 6.86 (d, *J* = 8.8 Hz, 2H), 5.50–5.38 (m, 2H), 4.59 (d, *J* = 4.0 Hz, 1H), 4.44–4.36 (m, 3H), 3.78 (s, 3H), 3.65–3.50 (m, 3H), 2.39–2.26 (m, 2H), 2.01 (q, *J* = 6.4 Hz, 2H), 1.81 (quint, *J* = 6.4 Hz, 2H), 1.26 (bs, 18H), 0.88 (t, *J* = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 159.3, 139.1, 132.4, 130.9, 129.5, 128.5, 128.0, 127.7, 125.2, 114.0, 76.3, 72.8, 71.5, 66.9, 55.4, 34.7, 32.1, 32.1, 29.9, 29.9, 29.8, 29.6, 29.6, 27.7, 22.9, 14.3; LRMS(ESI) *m/z* for C₃₂H₄₉O₃ [M + H]⁺ calcd: 503.35, found: 503.25.

Synthesis of S13{i17}, (R,Z)-1-(((3-(benzyloxy)-15-methylhexadec-5-en-1-yl)oxy)methyl)-4-methoxybenzene



Yield: 92%; ¹H NMR (400 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.33–7.23 (m, 7H), 6.86 (d, *J* = 8.8 Hz, 2H), 5.51–5.39 (m, 2H), 4.58 (d, *J* = 11.6 Hz, 1H), 4.44–4.36 (m, 3H), 3.79 (s, 3H), 3.66–3.50 (m, 3H), 2.39–2.25 (m, 2H), 2.02 (q, *J* = 6.8 Hz, 2H), 1.81 (quin, *J* = 6.6 Hz, 2H), 1.51 (sep, *J* = 6.6 Hz, 1H), 1.33–1.26 (m, 12H), 1.17–1.12 (m, 2H), 0.86 (d, *J* = 6.4 Hz, 6H); LRMS(ESI) *m/z* for C₃₂H₄₉O₃ [M + H]⁺ calcd: 503.35, found: 503.25.

Synthesis of S13{a17}, 1-(((3(R,Z)-3-(benzyloxy)-14-methylhexadec-5-en-1-yl)oxy)methyl)-4-methoxybenzene



Yield: 99%; ¹H NMR (500 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.34–7.22 (m, 7H), 6.87 (d, *J* = 8.5 Hz, 2H), 5.49–5.39 (m, 2H), 4.58 (d, *J* = 17.0 Hz, 1H), 4.44–4.37 (m, 3H), 3.79 (s, 3H), 3.64–3.60 (m, 1H), 3.60–3.51 (m, 2H), 2.37–2.27 (m, 2H), 2.02 (q, *J* = 7.0 Hz, 2H), 1.84–1.78 (m, 2H), 1.35–1.23 (m, 14H), 1.16–1.08 (m, 1H), 0.87–0.83 (m, 6H); ¹³C NMR (75 MHz, CDCl₃) δ 159.3, 139.1,


132.4, 130.9, 129.5, 128.5, 128.0, 127.7, 125.2, 114.0, 76.3, 72.8, 71.5, 66.9, 55.5, 36.9, 34.7, 34.6, 32.1, 30.2, 29.9, 29.8, 29.7, 29.6, 27.7, 27.3, 19.4, 11.6; LRMS(ESI) m/z for $C_{32}H_{49}O_3$ $[M + H]^+$ calcd: 503.35, found: 503.25.

General procedure of PMB deprotection




S13 was dissolved in TFA/DCM (1:20, v/v, 0.1 M for **S13**) at 0 °C and the reaction mixture was stirred for 4 hr. After the completion of reaction monitored by TLC, reaction mixture was diluted with EtOAc and washed with $NaHCO_3(aq.)$. Organic layer was dried over anhydrous $Na_2SO_4(s)$ and condensed under reduced pressure. The residue was and purified by silica-gel flash column chromatography (EtOAc:Hex = 1:10 to 1:5 gradient elution) to provide the desired product.

Synthesis of OH-S13{n15}, (R,Z)-3-(benzyloxy)pentadec-5-en-1-ol




Yield: 59%; 1H NMR (300 MHz, $CDCl_3$, reference peak TMS at 0.00 ppm) δ 7.38–7.27 (m, 5H), 5.54–5.46 (m, 1H), 5.42–5.34 (m, 1H), 4.68 (d, $J = 11.4$ Hz, 1H), 4.49 (d, $J = 11.4$ Hz, 1H), 3.34–3.64 (m, 3H), 2.50–2.28 (m, 3H), 2.07–1.99 (m, 2H), 1.84–1.76 (m, 1H), 1.27 (bs, 14H), 0.88 (t, $J = 6.6$ Hz, 3H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 138.5, 132.8, 128.7, 128.1, 127.9, 124.7, 78.7, 71.3, 61.2, 36.3, 32.1, 31.5, 29.8, 29.8, 29.6, 29.6, 27.7, 22.9, 14.3; LRMS(ESI) m/z for $C_{22}H_{37}O_2$ $[M + H]^+$ calcd: 332.27, found: 333.20.

Synthesis of OH-S13{n16}, (R,Z)-3-(benzyloxy)hexadec-5-en-1-ol




Yield: 77% 1H NMR (400 MHz, $CDCl_3$, reference peak TMS at 0.00 ppm) δ 7.34–7.25 (m, 5H), 5.53–5.47(m, 1H), 5.41–5.35(m, 1H), 4.67 (d, $J = 11.2$ Hz, 1H), 4.49 (d, $J = 11.2$ Hz, 1H), 3.78–3.67 (m, 3H), 2.48–2.42 (m, 1H), 2.36–2.28 (m, 2H), 2.06–1.99 (m, 2H), 1.83–1.72 (m, 2H), 1.26 (bs, 16H), 0.88 (t, $J = 6.2$ Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 138.5, 132.8, 128.7, 128.1, 128.0, 124.7, 78.7, 71.3, 61.2, 36.3, 32.1, 31.5, 29.9, 29.8, 29.8, 29.6, 29.6, 27.7, 22.9, 14.3; LRMS(ESI) m/z for $C_{23}H_{39}O_2$ $[M + H]^+$ calcd: 347.29, found: 347.25.

Synthesis of OH-S13{n17}, (R,Z)-3-(benzyloxy)heptadec-5-en-1-ol



Yield: 74%; 1H NMR (300 MHz, $CDCl_3$, reference peak TMS at 0.00 ppm) δ 7.35–7.28 (m, 5H), 5.54–5.46 (m, 1H), 5.42–5.34 (m, 1H), 4.68 (d, $J = 11.4$ Hz, 1H), 4.49 (d, $J = 11.4$ Hz, 1H), 3.76–3.64 (m, 3H), 2.50–2.27 (m, 3H), 2.04 (q, $J = 6.6$ Hz, 2H), 1.81–1.73 (m, 2H), 1.26 (bs, 18H), 0.88 (t, $J = 6.6$ Hz, 3H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 138.5, 132.8, 128.7, 128.1, 128.0, 124.7, 78.7, 71.3, 61.1, 36.3, 32.1, 31.5, 29.9, 29.9, 29.8, 29.8, 29.6, 29.4, 27.7, 22.9, 14.3; LRMS(ESI) m/z for $C_{24}H_{41}O_2$ $[M + H]^+$ calcd: 361.30, found: 361.25.


Synthesis of OH-S13{i17}, (R,Z)-3-(benzyloxy)-15-methylhexadec-5-en-1-ol



Yield: 78%; $^1\text{H NMR}$ (300 MHz, CDCl_3 , reference peak TMS at 0.00 ppm) δ 7.33–7.26 (m, 5H), 5.57–5.49 (m, 1H), 5.43–5.34 (m, 1H), 4.60 (q, J = 10.8 Hz, 2H), 3.97–3.87 (m, 1H), 2.58 (d, J = 5.1 Hz, 2H), 2.48–2.29 (m, 2H), 2.05–1.97 (m, 2H), 1.51 (sep, J = 6.6 Hz, 1H), 1.26 (m, 12H), 1.17–1.12 (m, 2H), 0.86 (d, J = 6.6 Hz); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 177.2, 138.1, 133.4, 128.4, 127.8, 127.7, 123.8, 75.6, 71.7, 39.1, 31.7, 30.0, 29.7, 29.6, 29.4, 29.3, 28.0, 27.5, 27.4, 22.7; LRMS(ESI) m/z for $\text{C}_{24}\text{H}_{41}\text{O}_2$ [$\text{M} + \text{H}$] $^+$


calcd: 361.30, found: 361.25.

Synthesis of OH-S13{a17}, (3R,Z)-3-(benzyloxy)-14-methylhexadec-5-en-1-ol




Yield: 84%; $^1\text{H NMR}$ (300 MHz, CDCl_3 , reference peak TMS at 0.00 ppm) δ 7.33–7.26 (m, 5H), 5.57–5.49 (m, 1H), 5.42–5.34 (m, 1H), 4.60 (q, J = 11.7 Hz, 2H), 3.93 (quint, J = 6.0 Hz, 1H), 2.59 (d, J = 5.7 Hz, 2H), 2.54–2.29 (m, 2H), 2.02 (q, J = 6.9 Hz, 2H), 1.27 (bs, 13H), 1.16–1.07 (m, 2H), 0.85 (t, J = 6.9 Hz, 6H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 176.6, 138.2, 133.6, 128.6, 128.0, 128.0, 123.9, 75.8, 71.9, 39.4, 36.9, 34.6, 31.8, 30.2, 29.8, 29.8, 29.7, 29.6, 27.7, 27.3, 19.4, 11.6; LRMS(ESI) m/z for $\text{C}_{24}\text{H}_{41}\text{O}_2$ [$\text{M} + \text{H}$] $^+$ calcd: 361.30, found: 361.25.

General procedure of oxidation




To a solution of **OH-S13** (1.0 equiv.) in acetone (0.1 M for **OH-S13**) was added Jones reagent (2.0 equiv.) at 0 °C, then the reaction mixture was stirred for 2.5 hr. After the completion of the reaction monitored by TLC, the reaction mixture was diluted with EtOAc (2 mL) and washed with 1N HCl (3 mL). Organic layer was dried over anhydrous $\text{Na}_2\text{SO}_4(\text{s})$ and condensed under reduced pressure. The residue was purified by silica-gel flash column chromatography (EtOAc:Hex = 1:8 to 1:5 gradient elution with 0.5% AcOH) to provide the desired product.

Synthesis of S14{n15}, (R,Z)-3-(benzyloxy)pentadec-5-enoic acid




Yield: 76%; $^1\text{H NMR}$ (400 MHz, CDCl_3 , reference peak TMS at 0.00 ppm) δ 7.33–7.26 (m, 5H), 5.56–5.49 (m, 1H), 5.41–5.35 (m, 1H), 4.60 (q, J = 11.8 Hz, 2H), 3.93 (quint, J = 6.0 Hz, 1H), 2.60–2.57 (m, 2H), 2.46–2.38 (m, 1H), 2.35–2.31 (m, 1H), 2.02 (q, J = 7.2 Hz, 2H), 1.26 (bs, 14H), 0.88 (t, J = 7.2 Hz, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 177.3, 138.3, 133.6, 128.6, 128.0, 127.9, 124.0, 75.8, 71.9, 39.5, 32.1, 31.8, 29.8, 29.8, 29.5, 27.7, 22.9, 14.3.

Synthesis of S14{n16}, (R,Z)-3-(benzyloxy)hexadec-5-enoic acid




Yield: 61%; $^1\text{H NMR}$ (300 MHz, CDCl_3 , reference peak TMS at 0.00 ppm) δ 7.33–7.28 (m, 5H), 5.57–5.49 (m, 1H), 5.42–5.34 (m, 1H), 4.60 (q, $J = 11.4$ Hz, 2H), 3.93 (quint, $J = 6.0$ Hz, 1H), 2.58 (d, $J = 5.1$ Hz, 2H), 2.49–2.29 (m, 2H), 2.02 (q, $J = 6.6$ Hz, 2H), 1.26 (bs, 16H), 0.88 (t, $J = 6.6$ Hz, 3H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 177.0, 138.3, 133.6, 128.6, 128.0, 127.9, 124.0, 75.8, 71.9, 39.5, 32.1, 31.9, 29.9, 29.8, 29.6, 27.7, 22.9, 14.3.

Synthesis of S14{n17}, (R,Z)-3-(benzyloxy)heptadec-5-enoic acid




Yield: 76%; $^1\text{H NMR}$ (300 MHz, CDCl_3 , reference peak TMS at 0.00 ppm) δ 7.33–7.25 (m, 5H), 5.57–5.49 (m, 1H), 5.42–5.34 (m, 1H), 4.60 (q, $J = 10.8$ Hz, 2H), 3.93 (quint, $J = 6.0$ Hz, 1H), 2.58 (dd, $J = 6.3, 2.4$ Hz, 2H), 2.46–2.29 (m, 2H), 2.02 (q, $J = 6.9$ Hz, 2H), 1.26 (bs, 18H), 0.89 (t, $J = 6.9$ Hz, 3H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 177.3, 138.3, 133.6, 128.6, 128.0, 127.9, 124.0, 75.8, 71.9, 39.5, 32.1, 31.9, 29.9, 29.9, 29.8, 29.6, 27.7, 22.9, 14.3; LRMS(ESI) m/z for $\text{C}_{24}\text{H}_{37}\text{O}_3$ $[\text{M} - \text{H}]^-$ calcd: 373.28, found: 373.10.

Synthesis of S14{i17}, (R,Z)-3-(benzyloxy)-15-methylhexadec-5-enoic acid



Yield: 96%; $^1\text{H NMR}$ (300 MHz, CDCl_3 , reference peak TMS at 0.00 ppm) δ 7.33–7.26 (m, 5H), 5.57–5.49 (m, 1H), 5.43–5.34 (m, 1H), 4.60 (q, $J = 10.8$ Hz, 2H), 3.97–3.87 (m, 1H), 2.58 (d, $J = 5.1$ Hz, 2H), 2.48–2.29 (m, 2H), 2.05–1.97 (m, 2H), 1.51 (sep, $J = 6.6$ Hz, 1H), 1.26 (m, 12H), 1.17–1.12 (m, 2H), 0.86 (d, $J = 6.6$ Hz); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 177.2, 138.1, 133.4, 128.4, 127.8, 127.7, 123.8, 75.6, 71.7, 39.1, 31.7, 30.0, 29.7, 29.6, 29.4, 29.3, 28.0, 27.5, 27.4, 22.7; LRMS(ESI) m/z for $\text{C}_{24}\text{H}_{37}\text{O}_3$ $[\text{M} - \text{H}]^-$ calcd: 373.28, found: 373.10.


Synthesis of S14{a17}, (3R,Z)-3-(benzyloxy)-14-methylhexadec-5-enoic acid




Yield: 75%; $^1\text{H NMR}$ (300 MHz, CDCl_3 , reference peak TMS at 0.00 ppm) δ 7.33–7.26 (m, 5H), 5.57–5.49 (m, 1H), 5.42–5.34 (m, 1H), 4.60 (q, $J = 11.7$ Hz, 2H), 3.93 (quint, $J = 6.0$ Hz, 1H), 2.59 (d, $J = 5.7$ Hz, 2H), 2.54–2.29 (m, 2H), 2.02 (q, $J = 6.9$ Hz, 2H), 1.27 (bs, 13H), 1.16–1.07 (m, 2H), 0.85 (t, $J = 6.9$ Hz, 6H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 176.6, 138.2, 133.6, 128.6, 128.0, 128.0, 123.9, 75.8, 71.9, 39.4, 36.9, 34.6, 31.8, 30.2, 29.8, 29.8, 29.7, 29.6, 27.7, 27.3, 19.4, 11.6; LRMS(ESI) m/z for $\text{C}_{24}\text{H}_{37}\text{O}_3$ $[\text{M} - \text{H}]^-$ calcd: 373.28, found: 373.10.

B. Synthesis of α -galactosylsphingoid building blocks

In the case of sphinganine building blocks, α -galactosylsphinganine having iodide (**S22**) was prepared from Garner aldehyde. In a similar manner as acyl building blocks, sphingoid building blocks (**S23**{*i*17}–**S23**{*n*18}) were generated by decoration of terminal structures via sp^3 – sp^3 cross-coupling.




Synthesis of **S16**, *tert*-butyl(dec-9-yn-1-yloxy)diphenylsilane



To a solution of 9-decyne-1-ol (25.9 mmol) in dry DCM (150 mL) were added *tert*-butyl(chloro)diphenylsilane (33.7 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (33.7 mmol) under Ar(g) at 0 °C.

After being stirred for 1 hr at 0 °C, the reaction was warmed up to ambient temperature and stirred for 4 hr. After the completion of the reaction monitored by TLC, the reaction mixture was diluted with EtOAc (100 mL) and washed with brine. Organic layer was dried over anhydrous Na₂SO₄ (s) and condensed under reduced pressure. The residue was purified by silica-gel flash column chromatography (EtOAc:Hex = 1:80 to 1:40 gradient elution) to provide the desired product (9.78g, 96%). ¹H NMR (500 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.68–7.66 (m, 4H), 7.44–7.36 (m, 6H), 3.65 (t, *J* = 7.0 Hz, 2H), 2.18 (td, *J* = 7.0, 2.5 Hz, 2H), 1.94 (t, *J* = 2.5 Hz, 1H), 1.58–1.49 (m, 4H), 1.39–1.31 (m, 4H), 1.28–1.26 (m, 4H), 1.05 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 135.8, 134.4, 129.7, 127.8, 85.0, 68.3, 64.2, 32.8, 29.4, 29.3, 28.9, 28.7, 27.1, 25.9, 19.4, 18.6; LRMS(ESI) *m/z* for C₂₆H₃₇OSi [M + H]⁺ calcd: 393.25, found: 393.20.


Synthesis of **S17**, *tert*-butyl (S)-4-((R)-11-((*tert*-butyldiphenylsilyl)oxy)-1-hydroxyundec-2-yn-1-yl)-2,2-dimethylloxazolidine-3-carboxylate



To a solution of **S16** (10.7 mmol) in dry THF (80 mL) was added *n*-butyllithium (12.9 mmol) slowly under Ar(g) at -78 °C and the reaction mixture was stirred for 45 min at -78 °C. Garner's aldehyde (11.8 mmol) in dry THF (20 mL) was added to reaction mixture dropwise at -78 °C. The reaction mixture was stirred at ambient temperature for overnight. After the completion of the reaction monitored by TLC, the reaction was quenched by adding NH₄Cl(aq.) (50 mL) and organic layer was extracted with


EtOAc (50 mL × 3). Organic layer was dried over anhydrous Na₂SO₄ (s) and condensed under reduced pressure. The residue purified by silica-gel flash column chromatography (EtOAc:Hex = 1:10 to 1:5 gradient elution) to provide the desired product (5.65g, 85%). ¹H NMR (400 MHz, CDCl₃, reference peak CDCl₃ at 7.26 ppm) δ 7.68–7.66 (m, 4H), 7.44–7.35 (m, 6H), 4.74 (d, *J* = 7.6 Hz, 1H), 4.51 (d, *J* = 7.6 Hz, 1H), 4.13–4.06 (m, 2H), 3.90 (bs, 1H), 3.65 (t, *J* = 6.4 Hz, 2H), 2.19 (td, *J* = 7.2, 1.6 Hz, 2H), 1.58–1.45 (m, 20H), 1.38–1.31 (m, 4H), 1.28–1.24 (m, 4H), 1.05 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 135.8, 135.8, 134.4, 129.7, 127.8, 95.2, 64.2, 32.8, 29.5, 29.3, 29.1, 28.8, 28.6, 27.1, 26.0, 19.4, 19.0; LRMS(ESI) *m/z* for C₃₇H₅₅NaNO₅Si [M + Na]⁺ calcd: 644.37, found: 644.30.

Synthesis of S18, *tert*-butyl (S)-4-((R)-1-(benzyloxy)-11-((*tert*-butyldiphenylsilyl)oxy)undec-2-yn-1-yl)-2,2-dimethylazolidine-3-carboxylate




Sodium hydride (13.0 mmol) was dissolved in dry DMF (50 mL) under Ar(g) at 0 °C. **S17** in dry DMF (10 mL) was added to the reaction mixture slowly and the reaction mixture was stirred at 0 °C for 30 min. Tetrabutylammonium iodide (1.30 mmol) and benzyl chloride (13.0 mmol) were added to the reaction mixture and the reaction mixture was stirred at r.t. for overnight. After the completion of the reaction monitored by TLC, the reaction was quenched by adding NH₄Cl(aq.) (50 mL) at 0 °C and organic layer was extracted with EtOAc (40 mL × 3). The resultant was dried over anhydrous Na₂SO₄(s) and condensed under reduced pressure. The residue purified by silica-gel flash column chromatography (EtOAc:Hex = 1:20 to 1:15 gradient elution) to provide the desired product (5.73g, 81%). ¹H NMR (300 MHz, CDCl₃, reference peak CDCl₃ at 7.26 ppm) δ 7.68–7.66 (m, 4H), 7.42–7.32 (m, 11H), 4.82 (dd, *J* = 12.3, 5.1 Hz, 1H), 4.54 (d, *J* = 72 Hz, 1H), 4.52 (dd, *J* = 12.3, 5.1 Hz, 1H), 4.30–4.25 (m, 1H), 4.03 (d, *J* = 40.5 Hz, 1H), 4.01 (t, *J* = 7.8 Hz, 1H), 3.65 (t, *J* = 6.6 Hz, 2H), 2.24–2.17 (m, 2H), 1.62–1.47 (m, 15H), 1.36–1.26 (m, 12H), 1.05 (s, 9H); LRMS(ESI) *m/z* for C₄₄H₆₁NNaO₅Si [M + Na]⁺ calcd: 734.42, found: 734.50.

Synthesis of S19, (2S,3R)-2-azido-3-(benzyloxy)-13-((*tert*-butyldiphenylsilyl)oxy)tridec-4-yn-1-ol




S18 (3.62 mmol) was dissolved in HCl (4 M in dioxane)/THF (9 mL/9 mL) under Ar(g) and the reaction mixture was stirred at 0 °C. After the completion of the reaction monitored by TLC, the reaction mixture was poured to sat. NaHCO₃ (aq.) (40 mL) and organic layer was extracted with EtOAc (40 mL × 3). The organic layer was dried over anhydrous Na₂SO₄(s) and condensed under reduced pressure. The resultant, 4-(dimethylamino)pyridine (5.43 mmol) and imidazole-1-sulfonylazide¹ (7.25 mmol) were dissolved in MeOH (40 mL) and the reaction mixture was stirred at r.t. for overnight. After the completion of reaction monitored by TLC, the reaction mixture was diluted with DCM (50 mL) and washed with sat. NH₄Cl(aq.). The resulting organic layer was dried with anhydrous Na₂SO₄(s) and condensed under reduced pressure. The residue was purified by silica-gel flash column chromatography (EtOAc:Hex = 1:12 to 1:5 gradient elution) to provide the desired product (2.18g, 47%). ¹H NMR (400 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.68–7.66 (m, 4H), 7.43–7.27 (m, 11H), 4.84 (d, *J* = 12.0 Hz, 1H), 4.52 (d, *J* = 12.0 Hz, 1H), 4.28–4.26 (m, 1H), 3.82 (bs, 2H), 3.65 (t, *J* = 6.4 Hz, 2H), 3.60 (q, *J* = 5.2 Hz, 1H), 2.27 (td, *J* = 7.2, 1.6 Hz, 2H), 2.05 (bs, 1H), 1.58–1.51 (m, 4H), 1.41–1.32 (m, 4H), 1.29–1.26 (m, 4H), 1.05 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 137.1, 135.6, 134.1, 129.5, 128.5, 128.0, 128.0, 127.6, 89.8, 75.3, 70.7, 69.8, 65.6, 64.0, 62.3, 32.5, 29.2, 29.1, 28.8, 28.4, 26.9, 25.7, 19.2, 18.8; LRMS(ESI) *m/z* for C₃₆H₄₈N₃O₃Si [M + H]⁺ calcd: 598.34, found: 598.20.

Synthesis of S20, (((11R,12S)-12-azido-11-(benzyloxy)-13-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)tridec-9-yn-1-yl)oxy)(*tert*-butyl)diphenylsilane




To a solution of 1-O-acetyl-2,3,4,6-tetra-O-benzyl-D-galactopyranoside (6.14 mmol) in dry DCM (50 mL) at 0 °C was added trimethylsilyl iodide (TMSI, 7.37 mmol). After being stirred for 30 min at 0 °C, the reaction was stopped by adding anhydrous toluene (30 mL) and residual TMSI was removed by azeotropic evaporation with anhydrous toluene 3 times. The resultant (slight yellow) was dissolved in anhydrous benzene (15 mL) and kept under Ar(g). In a separate round-bottom flask, molecular sieve (4 Å, 1 g), tetrabutylammonium iodide (TBAI, 22.1 mmol), **S19** (2.46 mmol) and diisopropylethylamine (7.37 mmol) were added into dry benzene (55 mL). The reaction mixture was stirred under Ar(g) at 65 °C for 10 min. As the complete dissolution of TBAI, the galactosyl iodide in dry benzene was added into this flask and the reaction mixture was stirred at 65 °C for 2 hr. After the completion of reaction monitored by TLC, the reaction mixture was poured into cold sat. NaHCO₃(aq.). Organic layer was extracted with EtOAc (50 mL × 3) and dried over anhydrous Na₂SO₄(s). The resulting mixture was condensed under reduced pressure and purified by silica-gel column chromatography (EtOAc:Hex = 1:20 to 1:3 gradient elution) to provide the desired product (1.49g, 54%). ¹H NMR (400 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.66 (dd, *J* = 7.6, 1.6 Hz, 4H), 7.41–7.23 (m, 26H), 4.93 (d, *J* = 11.2 Hz, 1H), 4.87 (d, *J* = 3.6 Hz, 1H), 4.83–4.75 (m, 3H), 4.73–4.65 (m, 2H), 4.56 (d, *J* = 12 Hz, 1H), 4.48–4.42 (m, 2H), 4.40–4.36 (m, 1H), 4.31–4.30 (m, 1H), 4.04 (dd, *J* = 10.0, 3.6 Hz, 1H), 3.98–3.86 (m, 4H), 3.80–3.76 (m, 1H), 3.67–3.62 (m, 3H), 3.53–3.50 (m, 2H), 2.21 (td, *J* = 7.2, 1.6 Hz, 2H), 1.53 (septet, *J* = 7.2 Hz, 4H), 1.42–1.21 (m, 8H), 1.04 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 139.0, 138.8, 138.2, 137.7, 135.8, 134.4, 129.7, 128.6, 128.5, 128.5, 128.4, 128.0, 128.0, 127.9, 127.9, 127.9, 127.8, 127.7, 127.7, 127.7, 127.6, 98.8, 89.7, 79.0, 76.6, 75.2, 75.2, 75.0, 73.7, 73.4, 70.8, 69.9, 69.4, 69.1, 67.6, 64.2, 64.1, 32.8, 29.9, 29.5, 29.3, 29.1, 28.8, 27.1, 26.0, 19.4, 19.0; LRMS(ESI) *m/z* for C₇₀H₈₂N₃O₈Si [M + H]⁺ calcd: 1120.58, found: 1120.30.

Synthesis of S21, *tert*-butyl ((2S,3R)-3-(benzyloxy)-13-(((*tert*-butyldiphenylsilyloxy)-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)tridec-4-yn-2-yl)carbamate



To a solution of **S20** (1.33 mmol) in benzene/H₂O (10 mL/0.1 mL) was added triphenylphosphine (2.67 mmol) and the reaction mixture was stirred at 60 °C for 3 hr. After the completion of reaction monitored by TLC, solvent was evaporated under reduced pressure and residual H₂O was removed by azeotropic evaporation with toluene three times. The resulting mixture was dissolved in DCM (10 mL) then di-*tert*-butyl dicarbonate (2.67 mmol), triethylamine (4.69 mmol) were added to the reaction mixture. After being stirred at r.t. for overnight, solvent was evaporated under reduced pressure and the residue was purified by silica-gel column chromatography (EtOAc:Hex = 1:10 to 1:5 gradient elution) to provide the desired product (1.28g, 80%). ¹H NMR (300 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.81–7.65 (m, 4H), 7.40–7.22 (m, 31H), 5.07 (d, *J* = 9.3 Hz, 1H), 4.92 (d, *J* = 11.4 Hz, 1H), 4.85 (d, *J* = 3.0 Hz, 1H), 4.80 (d, *J* = 11.7 Hz, 1H), 4.76–4.68 (m, 3H), 4.64–4.50 (m, 3H), 4.46–4.35 (m, 3H), 4.15–4.07 (m, 1H), 4.00 (dd, *J* = 9.9, 3.6 Hz, 1H), 3.92–3.83 (m, 3H), 3.76 (d, *J* = 5.1 Hz, 1=2H), 3.64 (t, *J* = 6.6 Hz, 2H), 3.48 (d, *J* = 6.6 Hz, 2H), 2.16 (td, *J* = 6.9, 1.5 Hz, 2H), 1.56–1.50 (m, 4H), 1.42 (s, 9H), 1.34–1.24 (m, 8H), 1.04 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 155.7, 139.1, 138.9, 138.8, 138.2, 138.1, 135.8, 134.4, 129.7, 128.6, 128.6, 128.5, 128.5, 128.4, 128.1, 128.1, 128.0, 127.9, 127.8, 127.8, 127.7, 127.6, 98.7, 88.7, 79.4, 79.1, 75.2, 75.0, 73.7, 73.3, 70.7, 69.7, 69.2, 69.0, 67.9, 64.2, 53.9, 32.8, 29.5, 29.3, 29.2, 28.9, 28.6, 27.1, 26.0, 19.4, 19.0; LRMS(ESI) *m/z* for C₇₅H₉₁NaNO₁₀Si [M + Na]⁺ calcd: 1216.63, found: 1216.45.


Synthesis of OH-S21, *tert*-butyl ((2S,3R)-3-(benzyloxy)-13-hydroxy-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)tridec-4-yn-2-yl)carbamate



To a solution of **S20** (0.228 mmol) at r.t. in THF (2 mL) was added TBAF (1 M in THF, 0.274 mL), then stirred at r.t. for 2.5 hr. When the reaction was completed checked by TLC, the reaction mixture was concentrated *in vacuo*. The residue was purified by silica-gel flash column chromatography (20% EA in hexane gradient to 33.33%) to obtain the desired product (0.218g, quantitative). ¹H NMR (300 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ

7.39–7.20 (m, 25H), 5.25 (d, *J* = 9.3 Hz, 1H), 4.93–4.89 (m, 1H), 4.86 (d, *J* = 3.0 Hz, 1H), 4.80 (m, 1H), 4.78–4.68 (m, 3H), 4.68–4.63 (m, 1H), 4.59–4.34 (m, 5H), 4.12–4.07 (m, 1H), 4.03–3.76 (m, 6H), 3.58 (t, *J* = 6.3 Hz, 2H), 3.49 (d, *J* = 6.6 Hz, 2H), 2.19–2.15 (m, 2H), 1.53–1.25 (m, 21H); ¹³C NMR (75 MHz, CDCl₃) δ 155.8, 139.0, 138.8, 138.7, 138.2, 138.1, 128.5, 128.5, 128.4, 128.4, 128.2, 128.1, 128.0, 127.8, 127.7, 127.7, 127.6, 127.6, 98.6, 88.5, 79.3, 79.1, 76.8, 75.1, 74.9, 73.6, 73.3, 73.2, 70.6, 69.6, 69.1, 68.9, 67.8, 63.0, 53.9, 32.8, 29.2, 28.9, 28.7, 28.6, 25.7, 18.8.


Synthesis of O-mesylated S21, (11R,12S)-11-(benzyloxy)-12-((*tert*-butoxycarbonyl)amino)-13-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)tridec-9-yn-1-yl methanesulfonate



To a solution of **OH-S21** (1.24 mmol) in THF were added methanesulfonyl chloride (1.87 mmol) and triethylamine (2.49 mL) and the reaction mixture was stirred at r.t. for 3 hr. After the completion of the reaction monitored by TLC, solvent was evaporated under reduced pressure. The residue was purified by silica-gel column chromatography (EtOAc:Hex = 1:5 to 1:2 gradient elution) to provide the desired product (1.28g, 99%). ¹H NMR (300 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ

7.39–7.21 (m, 25H), 5.08 (d, *J* = 9.0 Hz, 1H), 4.92 (d, *J* = 11.4 Hz, 1H), 4.85 (d, *J* = 3.0 Hz, 1H), 4.81 (d, *J* = 11.7 Hz, 1H), 4.76–4.69 (m, 3H), 4.64 (s, 1H), 4.58 (d, *J* = 12.6 Hz, 1H), 4.51 (d, *J* = 5.7 Hz, 1H), 4.43 (dd, *J* = 15.6, 3.3 Hz, 2H), 4.35 (quint, *J* = 2.4 Hz, 1H), 4.18 (t, *J* = 6.6 Hz, 2H), 4.13–4.09 (m, 1H), 4.00 (dd, *J* = 9.9, 3.6 Hz, 1H), 3.921 (bs, 1H), 3.87–3.83 (m, 2H), 3.77 (d, *J* = 5.1 Hz, 2H), 3.48 (d, *J* = 6.3 Hz, 2H), 2.97 (s, 3H), 2.17 (td, *J* = 6.9, 1.8 Hz, 2H), 1.72 (quint, *J* = 6.9 Hz, 2H), 1.52–1.46 (m, 2H), 1.42 (s, 9H), 1.40–1.21 (m, 8H); ¹³C NMR (75 MHz, CDCl₃) δ 155.7, 139.1, 138.9, 138.8, 138.2, 138.1, 128.6, 128.5, 128.5, 128.5, 128.4, 128.1, 128.0, 127.9, 127.7, 127.7, 127.6, 98.8, 86.6, 79.4, 79.1, 76.8, 75.2, 75.0, 73.7, 73.3, 70.7, 70.3, 69.7, 69.2, 69.0, 67.9, 53.9, 37.5, 29.3, 29.1, 29.0, 28.8, 28.6, 25.6, 18.9; LRMS(ESI) *m/z* for C₆₀H₇₅NaNO₁₂S [M + Na]⁺ calcd: 1056.49, found: 1056.30.

Synthesis of S22, *tert*-butyl ((2S,3R)-3-(benzyloxy)-13-iodo-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)tridec-4-yn-2-yl)carbamate



To a solution of **O-mesylated S21** (1.23 mmol) in acetone were added sodium iodide (6.17 mmol) and sodium carbonate (0.25 mmol), then the reaction mixture was stirred at 65 °C for 3 hr. After the completion of reaction monitored by TLC, solvent was evaporated under reduced pressure. The residue was purified by silica-gel column chromatography (EtOAc:Hex = 1:10 to 1:5 gradient elution) to provide the desired product (1.26g, 96%). ¹H NMR (300 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ

7.39–7.21 (m, 25H), 5.07 (d, *J* = 9.3 Hz, 1H), 4.92 (d, *J* = 11.4 Hz, 1H), 4.85 (d, *J* = 3.0 Hz, 1H), 4.81 (d, *J* = 11.7 Hz, 1H), 4.76–4.69 (m, 3H), 4.66 (s, 1H), 4.58 (d, *J* = 11.7 Hz, 1H), 4.51 (d, *J* = 6.3 Hz, 1H), 4.46–4.40 (m, 2H), 4.37–4.36 (m, 1H), 4.12 (q, *J* = 7.2 Hz, 1H), 4.01 (dd, *J* = 10.2, 3.6 Hz, 1H), 3.92 (bs, 1H), 3.90–3.83 (m, 2H), 3.77 (d, *J* = 5.1 Hz, 2H), 3.48 (d, *J* = 6.6 Hz, 2H), 3.15 (t, *J* = 6.9 Hz, 2H), 2.17 (t, *J* = 6.9 Hz, 2H), 1.79 (quint, *J* = 7.2 Hz, 2H), 1.58–1.26 (m, 19H); ¹³C NMR (75 MHz, CDCl₃) δ 155.7, 139.1, 138.9, 138.8, 138.2, 138.1, 128.6, 128.6, 128.5, 128.5, 128.4, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 98.8,


88.6, 79.4, 79.1, 75.2, 75.0, 73.7, 73.3, 70.7, 69.7, 69.2, 69.0, 67.9, 53.9, 33.7, 30.7, 29.1, 29.0, 28.8, 28.6, 18.9, 7.5; LRMS(ESI) m/z for $C_{59}H_{72}INaNO_9$ [$M + Na$] $^+$ calcd: 1088.41, found: 1088.30.

General procedure of the $Cu^{(I)}$ -mediated sp^3-sp^3 cross coupling



To a solution of **S22** (1.0 equiv.) in dry THF (0.1 M for **S22**) under Ar(g) were added alkylmagnesium halide (4.0 equiv.) and dilithium tetrachlorocuprate (0.4 equiv.) successively at 0 °C. The reaction mixture was stirred for 1.5 hr at 0 °C. After the completion of reaction monitored by TLC, the reaction was quenched by adding sat. $NaHCO_3$ (aq.) and organic layer was extracted with EtOAc three times and dried over anhydrous Na_2SO_4 (s). Resulting mixture was condensed under reduced pressure and purified by silica-gel flash column chromatography (EtOAc:Hex = 1:10 to 1:6 gradient elution) to provide the desired product.


Synthesis of S23{a17}, *tert*-butyl ((2S,3R)-3-(benzyloxy)-14-methyl-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)hexadec-4-yn-2-yl)carbamate



Yield: 59%; 1H NMR (300 MHz, $CDCl_3$, reference peak TMS at 0.00 ppm) δ 7.38–7.25 (m, 25H), 5.07 (d, $J = 9.0$ Hz, 1H), 4.92 (d, $J = 11.4$ Hz, 1H), 4.85 (d, $J = 2.7$ Hz, 1H), 4.80 (d, $J = 11.7$ Hz, 1H), 4.76–4.68 (m, 3H), 4.64 (s, 1H), 4.58 (d, $J = 11.7$ Hz, 1H), 4.51 (d, $J = 6.3$ Hz, 1H), 4.46 (s, 1H), 4.39 (dd, $J = 12.6, 5.4$ Hz, 2H), 4.14–3.90 (m, 1H), 4.00 (dd, $J = 9.9, 3.6$ Hz, 1H), 3.92 (bs, 1H), 3.90–3.83 (m, 2H), 3.76 (d, $J = 4.8$ Hz, 2H), 3.49 (d, $J = 6.6$ Hz, 2H), 2.17 (td, $J = 6.9$ Hz, 1.5 Hz, 2H), 1.48–1.42 (m, 11H), 1.36–1.23 (m, 13H), 1.16–1.06 (m, 2H), 0.85 (t, $J = 7.2$ Hz, 6H); ^{13}C NMR

(75 MHz, $CDCl_3$) δ 155.7, 139.1, 138.9, 138.8, 138.2, 138.1, 128.6, 128.5, 128.5, 128.5, 128.4, 128.3, 128.1, 128.1, 128.0, 127.9, 127.7, 127.6, 98.7, 88.8, 79.4, 79.1, 75.2, 75.0, 73.7, 73.3, 70.7, 69.7, 69.2, 69.0, 67.9, 53.9, 36.9, 34.6, 30.2, 29.8, 29.7, 29.4, 28.9, 28.6, 27.3, 19.4, 19.0, 11.6; LRMS(ESI) m/z for $C_{63}H_{81}NaNO_9$ [$M + Na$] $^+$ calcd: 1018.58, found: 1018.35.


Synthesis of S23{n17}, *tert*-butyl ((2S,3R)-3-(benzyloxy)-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)heptadec-4-yn-2-yl)carbamate



Yield: 68%; 1H NMR (300 MHz, $CDCl_3$, reference peak TMS at 0.00 ppm) δ 7.39–7.22 (m, 25H), 5.07 (d, $J = 8.7$ Hz, 1H), 4.92 (d, $J = 11.4$ Hz, 1H), 4.85 (d, $J = 3.0$ Hz, 1H), 4.81 (d, $J = 11.7$ Hz, 1H), 4.76–4.69 (m, 3H), 4.64 (s, 1H), 4.59 (d, $J = 5.7$ Hz, 1H), 4.51 (d, $J = 6.3$ Hz, 1H), 4.64 (s, 1H), 4.42–4.36 (m, 2H), 4.16–4.09 (m, 1H), 4.01 (dd, $J = 9.9, 3.6$ Hz, 1H), 3.92 (bs, 1H), 3.90–3.83 (m, 2H), 3.76 (d, $J = 5.1$ Hz, 2H), 3.48 (d, $J = 6.3$ Hz, 2H), 2.16 (td, $J = 7.2, 1.8$ Hz, 2H), 1.51–1.42 (m, 11H), 1.36–1.25

(m, 18H), 0.88 (t, $J = 6.9$ Hz, 3H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 155.7, 139.1, 138.9, 138.8, 138.2, 138.1, 128.6, 128.6, 128.5, 128.5, 128.4, 128.4, 128.1, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 98.7, 88.8, 79.4, 79.1, 75.2, 75.0, 73.7, 73.3, 70.7, 69.6, 69.1, 69.0, 67.9, 53.9, 32.1, 29.9, 29.8, 29.7, 29.6, 29.3, 29.2, 28.6, 28.0, 22.9, 18.9, 14.3; LRMS(ESI) m/z for $C_{63}H_{81}NaNO_9$ [$M + Na$] $^+$ calcd: 1018.58, found: 1018.35.


Synthesis of S23{n18}, *tert*-butyl ((2S,3R)-3-(benzyloxy)-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)octadec-4-yn-2-yl)carbamate



Yield: 44%; ¹H NMR (300 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.39–7.22 (m, 25H), 5.07 (d, *J* = 8.7 Hz, 1H), 4.92 (d, *J* = 11.4 Hz, 1H), 4.85 (d, *J* = 3.0 Hz, 1H), 4.81 (d, *J* = 11.7 Hz, 1H), 4.76–4.69 (m, 3H), 4.64 (s, 1H), 4.59 (d, *J* = 5.7 Hz, 1H), 4.51 (d, *J* = 6.3 Hz, 1H), 4.64 (s, 1H), 4.42–4.36 (m, 2H), 4.16–4.09 (m, 1H), 4.01 (dd, *J* = 9.9, 3.6 Hz, 1H), 3.92 (bs, 1H), 3.90–3.83 (m, 2H), 3.76 (d, *J* = 5.1 Hz, 2H), 3.48 (d, *J* = 6.3 Hz, 2H), 2.16 (td, *J* = 7.2, 1.8 Hz,

2H), 1.51–1.42 (m, 11H), 1.36–1.25 (m, 20H), 0.88 (t, *J* = 6.9 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 155.7, 139.1, 138.9, 138.8, 138.2, 138.1, 128.6, 128.6, 128.5, 128.5, 128.4, 128.4, 128.1, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 98.7, 88.8, 79.4, 79.1, 75.2, 75.0, 73.7, 73.3, 70.7, 69.6, 69.1, 69.0, 67.9, 53.9, 32.1, 29.9, 29.8, 29.6, 29.4, 29.2, 28.9, 28.6, 22.9, 19.0, 14.4; LRMS(ESI) *m/z* for C₆₄H₈₃NaNO₉ [M + Na]⁺ calcd: 1032.60, found: 1032.40.


Synthesis of S23{n19}, *tert*-butyl ((2S,3R)-3-(benzyloxy)-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)nonadec-4-yn-2-yl)carbamate




Yield: 59%; ¹H NMR (300 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.38–7.25 (m, 25H), 5.07 (d, *J* = 9.0 Hz, 1H), 4.92 (d, *J* = 11.1 Hz, 1H), 4.85 (d, *J* = 2.7 Hz, 1H), 4.81 (d, *J* = 11.7 Hz, 1H), 4.76–4.69 (m, 3H), 4.64 (s, 1H), 4.58 (d, *J* = 11.7 Hz, 1H), 4.51 (d, *J* = 6.0 Hz, 1H), 4.46 (s, 1H), 4.42–4.36 (m, 2H), 4.13–4.09 (m, 1H), 4.01 (dd, *J* = 10.2, 3.6 Hz, 1H), 3.92 (bs, 1H), 3.90–3.83 (m, 2H), 3.76 (d, *J* = 4.8 Hz, 2H), 3.49 (d, *J* = 6.6 Hz, 2H),

2.16 (td, *J* = 6.9, 1.5 Hz, 2H), 1.51–1.46 (m, 2H), 1.42 (s, 9H), 1.37–1.25 (m, 22H), 0.88 (t, *J* = 6.3 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 155.7, 139.1, 138.9, 138.8, 138.2, 138.1, 128.6, 128.5, 128.5, 128.5, 128.4, 128.1, 128.1, 128.0, 127.9, 127.7, 127.7, 127.6, 98.7, 88.8, 79.4, 79.1, 76.8, 75.9, 75.2, 75.0, 73.7, 73.3, 70.7, 69.7, 69.1, 69.0, 67.9, 53.9, 32.1, 29.9, 29.9, 29.8, 29.6, 29.4, 29.2, 28.9, 28.6, 22.9, 19.0, 14.3; LRMS(ESI) *m/z* for C₆₅H₈₅NaNO₉ [M + Na]⁺ calcd: 1046.61, found: 1046.40.

C. Construction of α -GalCer library




General procedure of Boc deprotection and amide coupling



S23 (1.0 equiv.) was dissolved in TFA/DCM (0.2 mL/2 mL) and the reaction mixture was stirred at r.t. for 3 hr. After the completion of reaction monitored by TLC, the reaction was quenched by adding sat. $\text{NaHCO}_3(\text{aq.})$ and organic layer was extracted with EtOAc (10 mL \times 3) and dried over anhydrous $\text{Na}_2\text{SO}_4(\text{s})$. The resulting mixture, **S14** (1.0 equiv.), *N*-3-dimethylaminopropyl-*N*'-ethylcarbodiimide hydrochloride (2.5 equiv.) and 4-(dimethylamino)pyridine (0.1 equiv.) were dissolved in dry THF (2 mL) and the reaction mixture was stirred at r.t. for overnight. After the completion of reaction monitored by TLC, the reaction mixture was diluted with EtOAc and was washed with brine. The resulting mixture was dried with anhydrous $\text{Na}_2\text{SO}_4(\text{s})$ and condensed under reduced pressure. The residue was purified by silica-gel flash column chromatography (EtOAc:Hex = 1:8 to 1:5 gradient elution) to provide the desired product.


Synthesis of S24}\{n18/n16\}, (R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)octadec-4-yn-2-yl)hexadec-5-enamide



Yield: 67%; $^1\text{H NMR}$ (500 MHz, CDCl_3 , reference peak TMS at 0.00 ppm) δ 7.35–7.18 (m, 30H), 6.61 (d, J = 8.5 Hz, 1H), 5.48–5.43 (m, 1H), 5.37–5.32 (m, 1H), 4.89 (d, J = 12.0 Hz, 1H), 4.82 (d, J = 3.5 Hz, 1H), 4.75–4.69 (m, 3H), 4.60 (t, J = 12.5 Hz, 2H), 4.53–4.43 (m, 5H), 4.41–4.36 (m, 2H), 3.98 (dd, J = 10.0, 3.5 Hz, 1H), 3.88–3.84 (m, 3H), 3.80–3.73 (m, 3H), 3.46 (dd, J = 7.5, 3.0 Hz, 2H), 2.35–2.25 (m, 4H), 2.10 (t, J = 7.0 Hz, 2H), 1.97 (q, J = 7.0 Hz, 2H), 1.44 (quint, J = 7.5 Hz, 2H), 1.29–1.25 (m, 36H), 0.88 (t, J = 7.0 Hz, 6H); $^{13}\text{C NMR}$

(75 MHz, CDCl_3) δ 171.2, 139.1, 138.9, 138.7, 138.6, 138.2, 138.0, 132.9, 128.6, 128.5, 128.4, 128.4, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 124.6, 98.8, 89.1, 79.1, 75.8, 75.1, 74.9, 73.6, 73.5, 73.5, 71.7, 70.7, 69.8, 69.0, 68.7, 67.6, 52.5, 41.7, 32.1, 32.1, 31.9, 29.9, 29.9, 29.8, 29.6, 29.4, 29.2, 28.9, 27.7, 22.9, 18.9, 14.3; LRMS(ESI) m/z for $\text{C}_{82}\text{H}_{110}\text{NO}_9$ [$\text{M} + \text{Na}$] $^+$ calcd: 1252.81, found: 1252.60.


Synthesis of S24{n18/n15}, (R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)octadec-4-yn-2-yl)pentadec-5-enamide



Yield: 87%; ¹H NMR (400 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.34–7.18 (m, 30H), 6.62 (d, *J* = 8.4 Hz, 1H), 5.49–5.43 (m, 1H), 5.38–5.32 (m, 1H), 4.89 (d, *J* = 11.6 Hz, 1H), 4.82 (d, *J* = 3.2 Hz, 1H), 4.74–4.69 (m, 3H), 4.60 (t, *J* = 11.2 Hz, 2H), 4.53–4.44 (m, 5H), 4.39–4.33 (m, 2H), 3.98 (dd, *J* = 9.6, 3.2 Hz, 1H), 3.87–3.84 (m, 3H), 3.80–3.76 (m, 3H), 3.46 (d, *J* = 6.4 Hz, 2H), 2.36–2.26 (m, 4H), 2.10 (t, *J* = 6.8 Hz, 2H), 1.97 (q, *J* = 6.8 Hz, 2H), 1.44 (quint, *J* = 7.2 Hz, 2H), 1.25 (bs,

34H), 0.88 (t, *J* = 6.8 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 171.2, 139.1, 138.9, 138.7, 138.6, 138.2, 138.0, 132.9, 128.6, 128.5, 128.4, 128.4, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 124.6, 98.8, 89.0, 79.1, 76.8, 76.7, 75.8, 75.0, 74.9, 73.6, 73.5, 73.2, 71.7, 70.7, 69.7, 69.0, 68.7, 67.6, 52.5, 41.7, 32.1, 32.1, 31.9, 29.9, 29.9, 29.9, 29.8, 29.6, 29.6, 29.5, 29.4, 29.4, 29.2, 28.9, 27.7, 22.9, 18.9, 14.3; LRMS(ESI) *m/z* for C₈₁H₁₀₈NO₉ [M + H]⁺ calcd: 1238.79, found: 1238.25.


Synthesis of S24{n18/i17}, (R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)octadec-4-yn-2-yl)-15-methylhexadec-5-enamide



Yield: 84%; ¹H NMR (400 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.33–7.18 (m, 30H), 6.59 (d, *J* = 8.8 Hz, 1H), 4.88 (d, *J* = 11.2 Hz, 1H), 4.80 (t, *J* = 2.8 Hz, 1H), 4.80 (d, *J* = 2.8 Hz, 1H), 4.73–4.67 (m, 3H), 4.63–4.56 (m, 3H), 4.52–4.42 (m, 5H), 4.39–4.34 (m, 2H), 3.97 (dt, *J* = 10.0, 3.2 Hz, 1H), 3.85–3.83 (m, 3H), 3.78–3.74 (m, 3H), 3.44 (d, *J* = 6.0 Hz, 2H), 2.34–2.22 (m, 4H), 2.08 (t, *J* = 6.8 Hz, 2H), 1.96 (q, *J* =

6.8 Hz, 2H), 1.53–1.39 (m, 4H), 1.23 (bs, 31H), 1.15–1.13 (m, 2H), 0.88–0.83 (m, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 171.2, 139.1, 138.9, 138.7, 138.6, 138.2, 138.0, 132.9, 128.6, 128.5, 128.5, 128.4, 128.4, 128.2, 128.2, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 124.6, 98.8, 89.1, 79.2, 76.8, 76.7, 75.8, 75.1, 75.0, 73.6, 73.5, 73.2, 71.7, 70.7, 69.8, 69.0, 68.7, 67.6, 52.5, 41.7, 39.3, 32.1, 31.9, 31.2, 30.2, 29.9, 29.9, 29.8, 29.8, 29.6, 29.6, 29.4, 29.2, 28.9, 28.2, 27.7, 27.6, 22.9, 22.9, 18.9, 14.3; LRMS(ESI) *m/z* for C₈₃H₁₁₁NaNO₉ [M + Na]⁺ calcd: 1288.82, found: 1288.50.


Synthesis of S24{n18/a17}, (3R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)octadec-4-yn-2-yl)-14-methylhexadec-5-enamide



Yield: 44%; ¹H NMR (500 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.33–7.18 (m, 30H), 6.62 (d, *J* = 8.5 Hz, 1H), 5.48–5.43 (m, 1H), 5.38–5.32 (m, 1H), 4.89 (d, *J* = 11.5 Hz, 1H), 4.82 (d, *J* = 3.0 Hz, 1H), 4.74–4.69 (m, 3H), 4.60 (t, *J* = 12.5 Hz, 2H), 4.53–4.43 (m, 5H), 4.38 (t, *J* = 12.5 Hz, 2H), 3.98 (d, *J* = 7.5 Hz, 1H), 3.85 (bs, 3H), 3.79–3.76 (m, 3H), 3.46 (d, *J* = 4.0 Hz, 2H), 2.35–2.25 (m, 4H), 2.10 (t, *J* = 6.5 Hz, 2H), 1.97 (q, *J* = 6.5 Hz,


2H), 1.45–1.42 (m, 2H), 1.24 (bs, 33H), 1.13–1.08 (m, 2H), 0.88–0.84 (m, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 170.9, 138.8, 138.6, 138.5, 138.4, 137.9, 137.7, 132.7, 128.3, 128.3, 128.2, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 127.4, 127.3, 124.4, 98.6, 88.8, 78.9, 76.6, 76.5, 75.6, 74.7, 73.4, 73.2, 72.9, 71.4, 70.5, 69.5, 68.8, 68.5, 67.4, 52.3, 41.5, 36.6, 34.4, 31.9, 31.7, 30.0, 29.7, 29.6, 29.5, 29.4, 29.4, 29.2, 29.0, 28.7, 27.5, 27.1, 22.7, 19.2, 18.7, 14.1, 11.4; LRMS(ESI) *m/z* for C₈₃H₁₁₁NaNO₉ [M + Na]⁺ calcd: 1288.82, found: 1288.50.

Synthesis of S24{n19/n16}, (R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)nonadec-4-yn-2-yl)hexadec-5-enamide




Yield: 76%; ¹H NMR (300 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.34–7.18 (m, 30H), 6.62 (d, *J* = 8.4 Hz, 1H), 5.50–5.42 (m, 1H), 5.39–5.31 (m, 1H), 4.89 (d, *J* = 11.4 Hz, 1H), 4.82 (d, *J* = 3.3 Hz, 1H), 4.75–4.68 (m, 3H), 4.65–4.59 (m, 2H), 4.57–4.44 (m, 5H), 4.40–4.35 (m, 2H), 3.98 (dd, *J* = 10.2, 3.6 Hz, 1H), 3.87–3.84 (m, 3H), 3.81–3.71 (m, 3H), 3.47 (d, *J* = 6.0 Hz, 2H), 2.36–2.26 (m, 4H), 2.10 (t, *J* = 6.6 Hz, 2H), 1.97 (q, *J* = 6.6 Hz, 2H), 1.48–1.41 (m, 2H), 1.25 (bs, 38H), 0.88 (t, *J* = 6.6 Hz, 6H); ¹³C NMR (75 MHz, CDCl₃) δ 171.2, 139.1, 138.9, 138.7, 138.2, 138.0, 132.9, 128.6, 128.5, 128.4, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 124.6, 98.8, 89.0, 79.1, 75.8, 75.1, 74.9, 73.6, 73.5, 73.2, 71.7, 70.7, 69.8, 69.0, 68.7, 67.6, 52.5, 41.7, 32.1, 31.9, 29.9, 29.9, 29.6, 29.4, 29.2, 28.9, 27.7, 22.9, 18.9, 14.3; LRMS(ESI) *m/z* for C₈₃H₁₁₁NO₉ [M + Na]⁺ calcd: 1288.82, found: 1288.55.

Synthesis of S24{n19/n15}, (R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)nonadec-4-yn-2-yl)pentadec-5-enamide




Yield: 78%; ¹H NMR (400 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.34–7.17 (m, 30H), 6.62 (d, *J* = 8.8 Hz, 1H), 5.49–5.43 (m, 1H), 5.38–5.32 (m, 1H), 4.89 (d, *J* = 11.2 Hz, 1H), 4.82 (d, *J* = 3.2 Hz, 1H), 4.74–4.69 (m, 3H), 4.60 (t, *J* = 11.2 Hz, 2H), 4.53–4.41 (m, 5H), 4.39–4.33 (m, 2H), 3.98 (dd, *J* = 9.6, 3.2 Hz, 1H), 3.87–3.74 (m, 3H), 3.80–3.75 (m, 3H), 3.46 (d, *J* = 6.0 Hz, 2H), 2.36–2.24 (m, 4H), 2.10 (t, *J* = 6.8 Hz, 2H), 1.97 (q, *J* = 6.8 Hz, 2H), 1.44 (quint, *J* = 7.2 Hz, 2H), 1.25 (bs, 36H), 0.88 (t, *J* = 6.8 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 171.2, 139.1, 138.9, 138.7, 138.6, 138.2, 138.0, 132.9, 128.6, 128.5, 128.4, 128.4, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 124.6, 98.8, 89.0, 79.1, 76.8, 76.7, 75.8, 75.0, 74.9, 73.6, 73.5, 73.2, 71.7, 70.7, 69.7, 69.0, 68.7, 67.6, 52.5, 41.7, 32.1, 32.1, 31.9, 29.9, 29.9, 29.9, 29.8, 29.6, 29.5, 29.4, 29.4, 29.2, 28.9, 27.7, 22.9, 18.9, 14.3; LRMS(ESI) *m/z* for C₈₂H₁₀₉NaNO₉ [M + Na]⁺ calcd: 1274.80, found: 1274.80.

Synthesis of S24{n19/i17}, (R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)nonadec-4-yn-2-yl)-15-methylhexadec-5-enamide




Yield: 78%; ¹H NMR (400 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.33–7.18 (m, 30H), 6.59 (d, *J* = 8.8 Hz, 1H), 5.47–5.41 (m, 1H), 5.37–5.30 (m, 1H), 4.88 (d, *J* = 11.2 Hz, 1H), 4.80 (d, *J* = 2.4 Hz, 1H), 4.73–4.6 (m, 3H), 4.59 (t, *J* = 11.2 Hz, 2H), 4.52–4.42 (m, 5H), 4.39–4.34 (m, 2H), 3.97 (ddd, *J* = 9.6, 3.4, 1.2 Hz, 1H), 3.85–3.83 (m, 3H), 3.78 (bs, 1H), 3.76–3.73 (m, 2H), 3.45 (d, *J* = 6.0 Hz, 2H), 2.34–2.23 (m, 4H), 2.08 (t, *J* = 6.8 Hz, 2H), 1.96 (q, *J* = 6.8 Hz, 2H), 1.51–1.39 (4H), 1.23 (bs, 33H), 1.16–1.01 (m, 2H), 0.88–0.84 (m, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 171.2, 139.1, 138.9, 138.7, 138.6, 138.2, 138.0, 132.9, 128.6, 128.5, 128.5, 128.4, 128.4, 128.2, 128.2, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 124.6, 98.8, 89.1, 79.2, 76.8, 76.7, 75.8, 75.1, 74.9, 73.6, 73.5, 73.2, 71.7, 70.7, 69.8, 69.0, 68.7, 67.6, 52.5, 41.7, 39.3, 32.1, 31.9, 31.2, 30.2, 29.9, 29.9, 29.9, 29.8, 29.8, 29.6, 29.6, 29.4, 29.2, 28.9, 28.2, 27.7, 27.7, 22.9, 22.9, 18.9, 14.3; LRMS(ESI) *m/z* for C₈₄H₁₁₄NO₉ [M + H]⁺ calcd: 1280.84, found: 1280.60.

Synthesis of S24{n19/a17}, (3R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)nonadec-4-yn-2-yl)-14-methylhexadec-5-enamide




Yield: 42%; ¹H NMR (500 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.33–7.18 (m, 30H), 6.62 (d, *J* = 8.5 Hz, 1H), 5.48–5.43 (m, 1H), 5.37–5.32 (m, 1H), 4.89 (d, *J* = 11.5 Hz, 1H), 4.82 (d, *J* = 2.5 Hz, 1H), 4.74–4.69 (m, 3H), 4.60 (t, *J* = 12.5 Hz, 2H), 4.53–4.43 (m, 5H), 4.38 (t, *J* = 12.5 Hz, 2H), 3.98 (dd, *J* = 9.5, 2.5 Hz, 1H), 3.85 (bs, 3H), 3.80–3.76 (m, 3H), 3.46 (d, *J* = 5.0 Hz, 2H), 2.35–2.26 (m, 4H), 2.09 (t, *J* = 6.5 Hz, 2H), 1.97 (q, *J* = 6.5 Hz, 2H), 1.45–1.41 (m, 2H), 1.25 (bs, 35H), 1.14–1.10 (m, 2H), 0.89–0.84 (m, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 171.2, 139.1, 138.9, 138.7, 138.6, 138.2, 138.0, 132.9, 128.6, 128.5, 128.4, 128.4, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 124.6, 98.8, 89.1, 79.1, 76.8, 76.7, 75.8, 75.0, 74.9, 73.6, 73.5, 73.2, 71.7, 70.7, 69.8, 69.8, 69.0, 68.7, 67.6, 52.5, 41.7, 36.9, 34.6, 32.1, 31.9, 30.2, 29.9, 29.9, 29.8, 29.7, 29.6, 29.6, 29.4, 29.2, 29.9, 27.7, 27.3, 22.9, 19.4, 18.9, 14.3, 11.6; LRMS(ESI) *m/z* for C₈₄H₁₁₄NO₉ [M + H]⁺ calcd: 1280.84, found: 1280.60.

Synthesis of S24{i17/n16}, (R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-15-methyl-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)hexadec-4-yn-2-yl)hexadec-5-enamide




Yield: 76%; ¹H NMR (300 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.34–7.18 (m, 30H), 6.61 (d, *J* = 8.4 Hz, 1H), 5.50–5.42 (m, 1H), 5.39–5.32 (m, 1H), 4.89 (d, *J* = 11.4 Hz, 1H), 4.82 (d, *J* = 3.3 Hz, 1H), 4.75–4.97 (m, 3H), 4.64 (d, *J* = 5.1 Hz, 2H), 4.57–4.41 (m, 5H), 4.40–4.35 (m, 2H), 3.98 (dd, *J* = 9.9, 3.6 Hz, 1H), 3.87–3.84 (m, 3H), 3.81–3.68 (m, 3H), 3.71–3.46 (d, *J* = 6.0 Hz, 2H), 2.36–2.23 (m, 4H), 2.10 (t, *J* = 6.6 Hz, 2H), 1.97 (q, *J* = 6.6 Hz, 2H), 1.55–1.40 (m, 4H), 1.25 (bs, 27H), 1.17–1.13 (m, 2H), 0.88–0.75 (m, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 171.2, 139.1, 138.9, 138.7, 138.6, 138.2, 138.0, 132.9, 128.6, 128.5, 128.4, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 124.6, 98.8, 89.0, 79.1, 76.8, 75.8, 75.1, 74.9, 73.6, 73.5, 73.2, 71.7, 70.7, 69.8, 69.0, 68.7, 67.6, 52.5, 41.7, 39.3, 32.1, 31.9, 30.1, 29.9, 29.9, 29.8, 29.6, 29.6, 29.4, 29.2, 28.9, 28.2, 27.6, 22.9, 18.9, 14.3; LRMS(ESI) *m/z* for C₈₁H₁₀₇NO₉ [M + Na]⁺ calcd: 1260.78, found: 1260.70.

Synthesis of S24{i17/n15}, (R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-15-methyl-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)hexadec-4-yn-2-yl)pentadec-5-enamide



Yield: 99%; ¹H NMR (300 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.34–7.18 (m, 30H), 6.61 (d, *J* = 8.4 Hz, 1H), 5.50–5.42 (m, 1H), 5.39–5.31 (m, 1H), 4.892 (d, *J* = 11.4 Hz, 1H), 4.82 (d, *J* = 3.3 Hz, 1H), 4.75–4.68 (m, 3H), 4.62 (d, *J* = 8.1 Hz, 2H), 4.55 (d, *J* = 8.1 Hz, 1H), 4.50–4.42 (m, 4H), 4.40–4.35 (m, 2H), 3.98 (dd, *J* = 9.9, 3.3 Hz, 1H), 3.87–3.84 (m, 3H), 3.81–3.75 (m, 3H), 3.46 (d, *J* = 6.3 Hz, 2H), 2.36–2.26 (m, 4H), 2.10 (t, *J* = 6.6 Hz, 2H), 1.97 (q, *J* = 6.6 Hz, 2H), 1.55–1.39 (m, 4H), 1.25 (bs, 27H), 1.17–1.13 (m, 2H), 0.90–0.85 (m, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 171.2, 139.1, 138.9, 138.7, 138.6, 138.2, 138.0, 132.9, 128.6, 128.5, 128.4, 128.4, 128.4, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 124.6, 98.8, 89.0, 79.2, 75.8, 75.1, 74.9, 73.6, 73.5, 73.2, 71.7, 70.7, 69.8, 69.0, 68.7, 67.6, 52.5, 41.7, 39.3, 32.1, 32.1, 31.9, 30.2, 29.9, 29.8, 29.6, 29.6, 29.5, 29.4, 29.2, 28.9, 28.2, 27.6, 22.9, 18.9, 14.3; LRMS(ESI) *m/z* for C₈₂H₁₁₁NaNO₉ [M + Na]⁺ calcd: 1246.77, found: 1246.35.


Synthesis of S24{i17/i17}, (R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-15-methyl-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)hexadec-4-yn-2-yl)-15-methylhexadec-5-enamide



Yield: 78%; ¹H NMR (500 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.38–7.17 (m, 30H), 6.61 (d, *J* = 8.5 Hz, 1H), 5.45 (m, 1H), 5.35 (m, 1H), 4.89 (d, *J* = 11.5 Hz, 1H), 4.82 (d, *J* = 3.5 Hz, 1H), 4.74–4.69 (m, 3H), 4.60 (t, *J* = 12.5 MHz, 2H), 4.53–4.43 (m, 5H), 4.38 (t, *J* = 13.0 Hz, 3H), 3.98 (dd, *J* = 10.5, 3.5 Hz, 1H), 3.87–3.82 (m, 3H), 3.80–3.75 (m, 3H), 3.48–3.44 (m, 2H), 2.35–2.23 (m, 4H), 2.10 (t, *J* = 7.0 Hz, 2H), 1.97 (q, *J* = 7.0 Hz, 2H), 1.54–1.47 (m, 1H), 1.45–1.41 (m, 1H), 1.24 (m, 26H),

1.14 (m, 4H), 0.86 (dd, *J* = 6.5, 2.0 Hz, 12H); ¹³C NMR (75 MHz, CDCl₃) δ 173.6, 171.0, 138.9, 138.7, 138.5, 138.5, 138.0, 137.8, 132.7, 128.4, 128.3, 128.2, 128.2, 128.0, 127.9, 127.8, 127.7, 127.6, 127.6, 127.4, 127.3, 124.4, 98.6, 88.9, 79.0, 75.6, 74.9, 74.8, 73.5, 73.3, 73.0, 71.5, 70.6, 69.6, 68.9, 68.5, 67.4, 52.3, 41.6, 39.1, 31.7, 30.0, 29.7, 29.6, 29.4, 29.2, 29.0, 28.7, 28.0, 27.4, 22.7, 18.7; LRMS(ESI) *m/z* for C₈₂H₁₀₉NaNO₉ [M + Na]⁺ calcd: 1274.80, found: 1274.60.


Synthesis of S24{i17/a17}, (3R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-15-methyl-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)hexadec-4-yn-2-yl)-14-methylhexadec-5-enamide



Yield: 19%; ¹H NMR (500 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.33–7.18 (m, 30H), 6.62 (d, *J* = 8.5 Hz, 1H), 5.48–5.43 (m, 1H), 5.37–5.36 (m, 1H), 4.89 (d, *J* = 11.5 Hz, 1H), 4.82 (d, *J* = 3.0 Hz, 1H), 4.74–4.69 (m, 3H), 4.60 (t, *J* = 12.5 Hz, 2H), 4.55–4.43 (m, 5H), 4.38 (t, *J* = 12.5 Hz, 2H), 3.98 (dd, *J* = 9.5, 3.0 Hz, 1H), 3.85 (bs, 3H), 3.77–3.73 (m, 3H), 3.46 (d, *J* = 5.0 Hz, 2H), 2.35–2.25 (m, 4H), 2.09 (t, *J* = 6.0 Hz, 2H), 1.99–1.95 (m, 2H), 1.53–1.41 (m, 4H), 1.25 (bs, 28H), 1.15–1.10 (m, 2H), 0.86 (d, *J* = 6.5 Hz, 12H); ¹³C

NMR (75 MHz, CDCl₃) δ 171.2, 139.1, 138.9, 138.7, 138.2, 138.0, 132.9, 128.6, 128.5, 128.5, 128.4, 128.2, 128.2, 128.0, 127.9, 127.8, 127.6, 127.5, 124.6, 98.8, 89.1, 79.1, 75.8, 75.0, 75.0, 73.7, 73.5, 73.2, 71.7, 70.8, 69.8, 69.0, 68.7, 67.6, 52.5, 41.8, 39.3, 36.9, 34.6, 31.9, 30.2, 30.2, 29.9, 29.9, 29.7, 29.6, 29.4, 29.2, 28.9, 28.2, 27.7, 27.3, 22.9, 19.4, 18.9, 11.6; LRMS(ESI) *m/z* for C₈₂H₁₀₉NaNO₉ [M + Na]⁺ calcd: 1274.80, found: 1274.60.

Synthesis of S24{a17/n16}, (3R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-14-methyl-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)hexadec-4-yn-2-yl)hexadec-5-enamide




Yield: 82%; ¹H NMR (500 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.35–7.18 (m, 30H), 6.62 (d, *J* = 8.5 Hz, 1H), 5.48–5.43 (m, 1H), 5.37–5.32 (m, 1H), 4.89 (d, *J* = 11.5 Hz, 1H), 4.82 (d, *J* = 3.5 Hz, 1H), 4.74–4.69 (m, 3H), 4.66–4.58 (m, 2H), 4.53–4.43 (m, 5H), 4.41–4.36 (m, 2H), 3.98 (dd, *J* = 10.0, 3.5 Hz, 1H), 3.38–3.84 (m, 3H), 3.80–3.74 (m, 3H), 3.47–3.45 (m, 2H), 2.35–2.26 (m, 4H), 2.10 (t, *J* = 6.5 Hz, 2H), 1.97 (q, *J* = 6.5 Hz, 2H), 1.44 (quint, *J* = 7.0 Hz, 2H), 1.25 (bs, 29H), 1.15–1.08 (m, 2H),

0.89–0.83 (m, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 171.2, 139.1, 138.9, 138.7, 138.6, 138.2, 138.0, 132.9, 128.6, 128.5, 128.4, 128.4, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 124.6, 98.8, 89.0, 79.1, 75.8, 75.1, 75.0, 73.6, 73.5, 73.2, 71.7, 70.7, 69.8, 69.0, 68.7, 67.8, 52.5, 41.7, 36.9, 34.6, 32.1, 32.1, 31.9, 20.2, 29.9, 29.7, 29.6,

29.6, 29.4, 29.2, 28.9, 27.7, 27.3, 22.9, 19.4, 18.9, 14.3, 11.6; LRMS(ESI) m/z for $C_{81}H_{107}NO_9$ $[M + Na]^+$ calcd: 1260.78, found: 1260.70.


Synthesis of S24{a17/n15}, (3R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-14-methyl-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)hexadec-4-yn-2-yl)pentadec-5-enamide



Yield: 74%; 1H NMR (400 MHz, $CDCl_3$, reference peak TMS at 0.00 ppm) δ 7.34–7.18 (m, 30H), 6.61 (d, $J = 8.8$ Hz, 1H), 5.49–5.43 (m, 1H), 5.38–5.32 (m, 1H), 4.89 (d, $J = 11.6$ Hz, 1H), 4.82 (d, $J = 3.6$ Hz, 1H), 4.74–4.69 (m, 3H), 4.66–4.55 (m, 2H), 4.53–4.44 (m, 5H), 4.01–4.35 (m, 2H), 3.98 (dd, $J = 9.6, 3.2$ Hz, 1H), 3.87–3.84 (m, 3H), 3.80–3.66 (m, 3H), 3.46 (d, $J = 5.6$ Hz, 2H), 2.36–2.26 (m, 4H), 2.10 (t, $J = 6.4$ Hz, 2H), 1.97 (q, $J = 6.8$ Hz, 2H), 1.46–1.40 (m, 2H), 1.25 (bs, 27H), 1.14–1.10 (m, 2H), 0.89–

0.83 (m, 9H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 171.2, 139.1, 138.9, 138.7, 138.6, 138.2, 138.0, 132.9, 128.6, 128.5, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.6, 127.5, 124.6, 98.8, 89.0, 79.1, 76.8, 76.7, 75.8, 75.0, 74.9, 73.6, 73.5, 73.5, 71.7, 70.7, 69.7, 69.0, 68.7, 67.6, 52.5, 41.7, 36.9, 34.6, 32.1, 32.1, 31.9, 30.2, 29.8, 29.8, 29.7, 29.6, 29.6, 29.5, 29.4, 29.2, 28.9, 27.7, 27.3, 22.8, 19.4, 18.9, 14.3, 11.6; LRMS(ESI) m/z for $C_{82}H_{111}NaNO_9$ $[M + Na]^+$ calcd: 1246.77, found: 1246.35.


Synthesis of S24{a17/i17}, (3R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-14-methyl-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)hexadec-4-yn-2-yl)-15-methylhexadec-5-enamide



Yield: 81%; 1H NMR (400 MHz, $CDCl_3$, reference peak TMS at 0.00 ppm) δ 7.34–7.18 (m, 30H), 6.61 (d, $J = 8.4$ Hz, 1H), 5.49–5.43 (m, 1H), 5.38–5.32 (m, 1H), 4.89 (d, $J = 12.0$ Hz, 1H), 4.82 (d, $J = 3.6$ Hz, 1H), 4.74–4.68 (m, 3H), 4.66–4.57 (m, 3H), 4.53–4.44 (m, 5H), 4.41–4.36 (m, 2H), 3.98 (dd, $J = 9.6, 3.2$ Hz, 1H), 3.87–3.84 (m, 3H), 3.80–3.75 (m, 3H), 3.49–3.86 (m, 2H), 2.36–2.24 (m, 4H), 2.10 (t, $J = 6.8$ Hz, 2H), 1.97 (q, $J = 6.4$ Hz, 2H), 1.54–1.40 (m, 4H), 1.25 (bs, 25H), 1.15–

1.07 (m, 4H), 0.86 (d, $J = 6.4$ Hz, 6H), 0.85–0.82 (m, 6H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 171.2, 139.1, 138.9, 138.7, 138.7, 138.2, 138.0, 132.9, 128.6, 128.5, 128.5, 128.4, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 128.5, 124.6, 98.8, 89.1, 79.2, 75.8, 75.1, 75.0, 73.7, 73.5, 73.2, 71.7, 70.8, 69.8, 69.1, 68.8, 67.6, 52.5, 41.8, 39.3, 36.9, 34.6, 31.9, 31.1, 30.3, 30.2, 29.9, 29.8, 29.7, 29.6, 29.4, 29.2, 28.9, 28.2, 27.7, 27.6, 27.3, 22.9, 19.4, 18.9, 11.6; LRMS(ESI) m/z for $C_{82}H_{109}NaNO_9$ $[M + Na]^+$ calcd: 1274.80, found: 1274.60.


Synthesis of S24{a17/a17}, (3R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-14-methyl-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)hexadec-4-yn-2-yl)-14-methylhexadec-5-enamide



Yield: 26%; ¹H NMR (500 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.33–7.18 (m, 30H), 6.62 (d, *J* = 8.5 Hz, 1H), 4.89 (d, *J* = 11.5 Hz, 1H), 4.85 (d, *J* = 4.0 Hz, 1H), 4.78–4.69 (m, 3H), 4.66–4.58 (m, 3H), 4.54–4.43 (m, 5H), 4.38 (t, *J* = 12.5 Hz, 2H), 3.98 (dd, *J* = 10.0, 3.5 Hz, 1H), 3.85 (bs, 3H), 3.80–3.73 (m, 3H), 3.46 (d, *J* = 6.0 Hz, 2H), 2.35–2.25 (m, 4H), 2.10 (t, *J* = 6.0 Hz, 2H), 1.97 (q, *J* = 6.5 Hz, 2H), 1.47–1.41 (m, 2H), 1.26 (bs, 28H), 1.13–1.07 (m, 2H), 0.86–0.83 (m, 12H); ¹³C NMR (75 MHz,

CDCl₃) δ 171.2, 139.1, 138.9, 138.7, 138.7, 138.2, 138.0, 132.9, 128.6, 128.5, 128.5, 128.4, 128.4, 128.2, 128.2, 128.0, 127.9, 127.8, 127.7, 127.6, 127.6, 127.5, 124.6, 98.8, 89.1, 79.2, 85.8, 75.1, 75.0, 73.7, 73.5, 73.2, 71.7, 70.8, 69.8, 69.0, 68.7, 67.6, 52.5, 41.8, 36.9, 34.6, 31.9, 30.2, 30.2, 29.9, 29.9, 29.7, 29.6, 29.4, 29.2, 28.9, 27.7, 27.3, 19.4, 18.9, 11.6; LRMS(ESI) *m/z* for C₈₂H₁₀₉NaNO₉ [M + Na]⁺ calcd: 1274.80, found: 1274.60.


Synthesis of S24{i17/n17}, (R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-15-methyl-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)hexadec-4-yn-2-yl)heptadec-5-enamide



Yield: 76%; ¹H NMR (400 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.34–7.20 (m, 30H), 6.62 (d, *J* = 8.4 Hz, 1H), 5.49–5.43 (m, 1H), 5.38–5.33 (m, 1H), 4.89 (d, *J* = 11.2 Hz, 1H), 4.82 (d, *J* = 2.8 Hz, 1H), 4.74–4.68 (m, 3H), 4.65–4.57 (m, 2H), 4.53–4.44 (m, 5H), 4.41–4.36 (m, 2H), 3.98 (dd, *J* = 9.6, 3.2 Hz, 1H), 3.87–3.84 (m, 3H), 3.80–3.76 (m, 3H), 3.46 (d, *J* = 6.0 Hz, 2H), 2.37–2.26 (m, 4H), 2.09 (t, *J* = 6.4 Hz, 2H), 1.97 (q, *J* = 6.4 Hz, 2H), 1.54–1.41 (m, 3H), 1.25 (bs, 30H), 1.46 (bs, 2H),

0.88–0.85 (m, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 171.2, 139.1, 138.9, 138.7, 138.6, 138.2, 138.0, 132.9, 128.6, 128.5, 128.4, 128.4, 128.4, 128.2, 128.2, 128.0, 127.9, 127.8, 127.7, 127.6, 127.6, 127.5, 124.6, 98.8, 89.1, 79.1, 76.8, 76.7, 75.8, 75.0, 75.0, 73.6, 73.5, 73.2, 71.7, 70.7, 69.8, 69.0, 68.7, 67.6, 52.5, 41.7, 39.3, 32.1, 31.9, 30.1, 29.9, 29.9, 29.8, 29.6, 29.6, 29.4, 29.2, 28.9, 28.2, 27.7, 27.6, 22.9, 22.9, 18.9, 14.3; LRMS(ESI) *m/z* for C₈₂H₁₀₉NO₉ [M + Na]⁺ calcd: 1274.80, found: 1274.60.


Synthesis of S24{a17/n17}, (3R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-14-methyl-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)hexadec-4-yn-2-yl)heptadec-5-enamide



Yield: 57%; ¹H NMR (400 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.34–7.20 (m, 30H), 6.63 (d, *J* = 8.4 Hz, 1H), 5.49–5.43 (m, 1H), 5.38–5.29 (m, 1H), 4.89 (d, *J* = 11.2 Hz, 1H), 4.82 (d, *J* = 3.2 Hz, 1H), 4.74–4.69 (m, 3H), 4.66–4.57 (m, 3H), 4.53–4.44 (m, 4H), 4.41–4.36 (m, 2H), 3.98 (dd, *J* = 9.6, 3.2 Hz, 1H), 3.87–3.84 (m, 3H), 3.80–3.86 (m, 3H), 3.46 (d, *J* = 6.4 Hz, 2H), 2.36–2.24 (m, 4H), 2.10 (t, *J* = 6.8 Hz, 2H), 1.97 (q, *J* = 6.8 Hz, 2H), 1.44 (quint, *J* = 6.8 Hz, 3H), 1.25 (bs, 30H),

1.14–1.09 (m, 2H), 0.89–0.83 (m, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 171.2, 139.1, 138.9, 138.7, 138.6, 138.2, 138.0, 132.9, 128.6, 128.5, 128.4, 128.4, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 124.6, 98.8, 89.0, 79.1, 76.8, 76.7, 75.8, 75.1, 74.9, 73.6, 73.5, 73.2, 71.7, 70.7, 69.8, 69.0, 68.7, 67.6, 53.6, 52.5, 41.7, 36.9, 34.6, 32.1, 31.9, 30.2, 29.9, 29.9, 29.8, 29.7, 29.6, 29.6, 29.4, 29.2, 28.9, 27.7, 27.3, 22.9, 19.4, 18.9, 14.3, 11.6; LRMS(ESI) *m/z* for C₈₂H₁₀₉NO₉ [M + Na]⁺ calcd: 1274.80, found: 1274.60.


Synthesis of S24{n17/n17}, (R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)heptadec-4-yn-2-yl)heptadec-5-enamide



Yield: 31%; ¹H NMR (400 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.36–7.20 (m, 30H), 6.63 (d, *J* = 8.8 Hz, 1H), 5.49–5.43 (m, 1H), 5.38–5.32 (m, 1H), 4.89 (d, *J* = 11.2 Hz, 1H), 4.82 (d, *J* = 3.2 Hz, 1H), 4.74–4.68 (m, 3H), 4.60 (t, *J* = 11.2 Hz, 2H), 4.56–4.44 (m, 5H), 4.41–4.36 (m, 2H), 3.98 (dd, *J* = 10.0, 3.2 Hz, 1H), 3.87–3.84 (m, 3H), 3.77 (s, 1H), 3.76–3.72 (m, 2H), 3.46 (d, *J* = 6.0 Hz, 2H), 2.36–2.26 (m, 4H), 2.10

(t, *J* = 6.8 Hz, 2H), 1.97 (q, *J* = 6.8 Hz, 2H), 1.44 (quint, *J* = 6.8 Hz, 2H), 1.26 (bs, 36H), 0.88 (t, *J* = 6.8 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 171.2, 139.1, 138.9, 138.7, 138.6, 138.2, 138.0, 132.9, 128.6, 128.5, 128.4, 128.4, 128.2, 128.2, 128.0, 127.9, 127.8, 127.8, 127.7, 127.6, 127.5, 124.6, 98.8, 89.0, 79.1, 76.8, 76.7, 75.8, 75.0, 74.9, 73.6, 73.5, 73.2, 71.7, 70.7, 69.7, 69.0, 68.7, 67.6, 60.6, 52.5, 41.7, 32.1, 31.9, 29.9, 29.9, 29.8, 29.8, 29.8, 29.6, 29.6, 29.4, 29.2, 28.9, 27.7, 22.9, 21.3, 18.9, 14.4, 14.3; LRMS(ESI) *m/z* for C₈₂H₁₀₉NO₉ [M + Na]⁺ calcd: 1274.80, found: 1274.60.


Synthesis of S24{n17/i17}, (R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)heptadec-4-yn-2-yl)-15-methylhexadec-5-enamide



Yield: 58%; ¹H NMR (400 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.34–7.19 (m, 30H), 6.62 (d, *J* = 8.8 Hz, 1H), 5.49–5.43 (m, 1H), 5.38–5.32 (m, 1H), 4.89 (d, *J* = 12.0 Hz, 1H), 4.82 (d, *J* = 3.6 Hz, 1H), 4.74–4.68 (m, 3H), 4.60 (t, *J* = 11.2 Hz, 2H), 4.53–4.44 (m, 5H), 4.41–4.35 (m, 2H), 3.98 (dd, *J* = 10.0, 3.6 Hz, 1H), 3.87–3.84 (m, 3H), 3.80–3.72 (m, 3H), 3.46 (dd, *J* = 6.6, 2.0 Hz, 2H), 2.36–2.26 (m, 4H), 2.01 (t, *J* = 6.4 Hz, 2H),

1.97 (q, *J* = 6.8 Hz, 2H), 1.54–1.40 (m, 3H), 1.24 (bs, 30H), 1.15–1.12 (m, 2H), 0.89–0.85 (m, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 171.2, 139.1, 138.9, 138.7, 138.6, 138.2, 138.0, 132.9, 128.6, 128.5, 128.4, 128.4, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 124.6, 98.8, 89.1, 79.1, 76.7, 75.8, 75.0, 74.9, 73.2, 71.7, 70.7, 69.7, 69.0, 68.7, 67.6, 52.5, 41.7, 39.3, 32.1, 31.9, 30.2, 29.9, 29.9, 29.8, 29.8, 29.6, 29.6, 29.4, 29.2, 28.9, 28.2, 27.7, 27.6, 22.9, 22.9, 18.9, 14.3; LRMS(ESI) *m/z* for C₈₂H₁₀₉NO₉ [M + Na]⁺ calcd: 1274.80, found: 1274.60


Synthesis of S24{n17/a17}, (3R,Z)-3-(benzyloxy)-N-((2S,3R)-3-(benzyloxy)-1-(((2S,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)heptadec-4-yn-2-yl)-14-methylhexadec-5-enamide



Yield: 62%; ¹H NMR (400 MHz, CDCl₃, reference peak TMS at 0.00 ppm) δ 7.38–7.16 (m, 30H), 6.62 (d, *J* = 8.4 Hz, 1H), 5.49–5.42 (m, 1H), 5.38–5.31 (m, 1H), 4.89 (d, *J* = 12.0 Hz, 1H), 4.81 (d, *J* = 3.2 Hz, 1H), 4.74–4.68 (m, 3H), 4.60 (t, *J* = 11.2 Hz, 2H), 4.53–4.43 (m, 5H), 4.40–4.35 (m, 2H), 3.98 (dd, *J* = 10.0, 3.2 Hz, 1H), 3.86–3.84 (m, 3H), 3.80–3.74 (m, 3H), 3.44 (d, *J* = 5.6 Hz, 2H), 2.36–2.24 (m, 4H), 2.09 (t, *J* = 6.8 Hz, 2H), 1.97 (q, *J* = 6.8 Hz, 2H), 1.44 (quint, *J* = 7.2 Hz, 2H), 1.24 (bs, 31H), 1.15–


1.08 (m, 2H), 0.89–0.83 (m, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 171.2, 139.1, 138.9, 138.7, 138.6, 138.2, 138.0, 132.9, 128.6, 128.5, 128.4, 128.4, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.8, 127.7, 127.6, 127.5, 124.6, 98.8, 89.0, 79.1, 76.8, 76.7, 75.8, 75.0, 74.9, 73.6, 73.5, 73.2, 71.7, 70.7, 69.7, 69.0, 68.7, 67.6, 52.5, 41.7, 36.9, 34.6, 32.1, 31.9, 30.2, 29.9, 29.9, 29.8, 29.7, 29.6, 29.6, 29.4, 29.2, 28.9, 27.7, 27.3, 22.9, 19.4, 18.9, 14.3, 11.6; LRMS(ESI) *m/z* for C₈₂H₁₀₉NO₉ [M + Na]⁺ calcd: 1274.80, found: 1274.60.

General procedure of benzyl deprotection and triple bond reduction via catalytic hydrogenation



To a solution of **S24** (1.0 equiv.) in MeOH/DCM (1.5/0.5 mL) was added Pd(OH)₂/C (100 wt%) and the reaction mixture was stirred under H₂ atmosphere (1 atm) for 10 hr. After the completion of reaction monitored by TLC, catalyst was removed by filtration through 0.45 μm PTFE syringe filter and washed with MeOH/DCM (3:1, v/v) solution. The resulting filtrate was concentrated under reduced pressure to provide desired products as white solid.


Synthesis of **SB2201**, (R)-3-hydroxy-N-((2S,3R)-3-hydroxy-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)octadecan-2-yl)hexadecanamide



Yield: quantitative; ¹H NMR (600 MHz, CDCl₃:CD₃OD = 1:1, reference peak CD₃OD at 0.00 ppm) δ 4.85 (d, *J* = 3.6 Hz, 1H), 3.99–3.97 (m, 2H), 3.93–3.92 (m, 1H), 3.87–3.68 (m, 7H), 3.64–3.61 (m, 1H), 2.40–2.28 (m, 2H), 1.55–1.41 (m, 6H), 1.35–1.27 (m, 46H), 0.90–0.86 (m, 6H); ¹³C NMR (125 MHz,

CDCl₃:CD₃OD = 1:1, reference peak CD₃OD at 49.0 ppm) δ 173.6, 100.4, 71.6, 71.5, 70.9, 70.4, 69.8, 69.3, 68.0, 62.3, 54.4, 44.4, 37.9, 34.6, 32.6, 30.3, 30.3, 30.0, 26.5, 26.2, 23.3, 14.4; LRMS(ESI) *m/z* for C₄₀H₇₉NaNO₉ [M + Na]⁺ calcd: 740.56, found: 740.60.


Synthesis of **SB2202**, (R)-3-hydroxy-N-((2S,3R)-3-hydroxy-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)octadecan-2-yl)pentadecanamide



Yield: quantitative; ¹H NMR (600 MHz, CD₃OD/CDCl₃ (1:1, v/v), reference peak TMS at 0.00 ppm): δ 4.85 (d, *J* = 3.6 Hz, 1H), 4.00–3.96 (m, 2H), 3.93–3.92 (m, 1H), 3.87–3.68 (m, 7H), 3.63 (t, *J* = 6.9 Hz, 1H), 2.40–2.37 (m, 1H), 2.32–2.28 (m, 1H), 1.55–1.41 (m, 4H), 1.35–1.27 (m, 46H), 0.89 (t, *J* = 6.9 Hz, 6H); ¹³C NMR (150 MHz, CD₃OD/CDCl₃ (1:1, v/v), reference

peak CD₃OD at 49.00 ppm): δ 173.6, 100.3, 71.6, 71.4, 70.8, 70.3, 69.7, 69.2, 67.9, 62.2, 54.3, 44.3, 37.9, 34.5, 32.5, 30.3, 30.2, 29.9, 26.4, 26.2, 23.2, 14.3; LRMS(ESI) *m/z* for C₃₉H₇₇NaNO₉ [M + Na]⁺ calcd: 726.55, found: 726.60.


Synthesis of **SB2203**, (R)-3-hydroxy-N-((2S,3R)-3-hydroxy-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)octadecan-2-yl)-15-methylhexadecanamide



Yield: quantitative; ¹H NMR (600 MHz, CDCl₃:CD₃OD = 1:1, reference peak CD₃OD at 0.00 ppm) δ 4.85 (d, *J* = 4.2 Hz, 1H), 4.00–3.95 (m, 2H), 3.92 (dd, *J* = 3.0, 1.2 Hz, 1H), 3.86 (dd, *J* = 10.2, 3.0 Hz, 1H), 3.83 (t, *J* = 6.6 Hz, 1H), 3.80–3.72 (m, 4H), 3.69 (dd, *J* = 10.2, 4.8 Hz, 1H), 3.63 (td, *J* = 7.5, 2.4 Hz, 1H), 2.38 (dd, *J* = 14.4, 3.0 Hz, 1H), 2.30 (dd, *J* = 14.4, 7.8 Hz, 1H), 1.56–1.13 (m, 5H), 1.27 (bs, 44H), 1.16 (q, *J* = 7.2 Hz, 2H), 0.88 (dd, *J* = 15.0, 6.6 Hz, 9H); ¹³C NMR

(125 MHz, CDCl₃:CD₃OD = 1:1, reference peak CD₃OD at 49.0 ppm) δ 173.5, 100.2, 71.6, 70.8, 70.3, 69.7, 69.2, 67.9, 62.2, 54.3, 44.3, 39.6, 37.8, 34.5, 32.5, 30.9, 30.5, 30.2, 29.9, 28.5, 28.0, 26.4, 26.1, 23.2, 22.9, 14.3; LRMS(ESI) m/z for C₄₁H₈₁NaNO₉ [M + Na]⁺ calcd: 754.58, found: 754.60.


Synthesis of SB2204, (3R)-3-hydroxy-N-((2S,3R)-3-hydroxy-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)octadecan-2-yl)-14-methylhexadecanamide



Yield: quantitative; ¹H NMR (600 MHz, CD₃OD/CDCl₃ (1:1, v/v), reference peak TMS at 0.00 ppm): δ 4.85 (d, J = 3.0 Hz, 1H), 4.00–3.96 (m, 2H), 3.93–3.92 (m, 1H), 3.87–3.68 (m, 7H), 3.64–3.61 (m, 1H), 2.40–2.37 (m, 1H), 2.32–2.28 (m, 1H), 1.55–1.41 (m, 7H), 1.36–1.27 (m, 42H), 1.17–1.11 (m, 2H), 0.90–0.84 (m, 9H); ¹³C NMR (150 MHz, CD₃OD/CDCl₃ (1:1, v/v), reference peak

CD₃OD at 49.00 ppm): δ 173.5, 100.2, 71.5, 70.3, 69.6, 69.2, 62.2, 54.3, 44.2, 37.8, 37.2, 35.0, 34.5, 32.4, 30.5, 30.2, 30.0, 29.9, 27.6, 26.4, 26.1, 23.2, 19.4, 14.3, 11.6; LRMS(ESI) m/z for C₄₁H₈₁NaNO₉ [M + Na]⁺ calcd: 754.58, found: 754.60.


Synthesis of SB2205, (R)-3-hydroxy-N-((2S,3R)-3-hydroxy-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)nonadecan-2-yl)hexadecanamide



Yield: quantitative; ¹H NMR (600 MHz, CDCl₃:CD₃OD = 1:1, reference peak CD₃OD at 0.00 ppm) δ 4.85 (d, J = 3.6 Hz, 1H), 4.01–3.97 (m, 2H), 3.93–3.92 (m, 1H), 3.87–3.68 (m, 7H), 3.64–3.61 (m, 1H), 2.40–2.28 (m, 2H), 1.56–1.40 (m, 7H), 1.35–1.27 (m, 47H), 0.90–0.85 (m, 6H); ¹³C NMR (125 MHz, CDCl₃:CD₃OD = 1:1,

reference peak CD₃OD at 49.0 ppm) δ 173.6, 100.4, 71.7, 70.9, 70.4, 69.8, 69.3, 68.0, 62.3, 54.4, 44.4, 37.9, 34.6, 32.6, 30.3, 30.3, 30.0, 26.3, 26.2, 23.3, 14.4; LRMS(ESI) m/z for C₄₁H₈₁NaNO₉ [M + Na]⁺ calcd: 754.58, found: 754.60.


Synthesis of SB2206, (R)-3-hydroxy-N-((2S,3R)-3-hydroxy-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)nonadecan-2-yl)pentadecanamide



Yield: quantitative; ¹H NMR (600 MHz, CD₃OD/CDCl₃ (1:1, v/v), reference peak TMS at 0.00 ppm): δ 4.85 (d, J = 3.6 Hz, 1H), 4.00–3.96 (m, 2H), 3.93–3.92 (m, 1H), 3.87–3.68 (m, 7H), 3.63 (t, J = 6.9 Hz, 1H), 2.40–2.37 (m, 1H), 2.32–2.28 (m, 1H), 1.55–1.41 (m, 4H), 1.38–1.27 (m, 48H), 0.89 (t, J = 6.9 Hz, 6H); ¹³C NMR (150 MHz, CD₃OD/CDCl₃ (1:1,


v/v), reference peak CD₃OD at 49.00 ppm): δ 173.6, 100.3, 71.5, 71.4, 70.8, 70.3, 69.7, 69.2, 67.9, 62.2, 54.3, 44.3, 37.9, 34.5, 32.5, 30.2, 30.2, 29.9, 26.4, 26.2, 23.2, 14.3; LRMS(ESI) m/z for C₄₀H₇₉NaNO₉ [M + Na]⁺ calcd: 740.56, found: 740.60.

Synthesis of SB2207, (R)-3-hydroxy-N-((2S,3R)-3-hydroxy-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)nonadecan-2-yl)-15-methylhexadecanamide




Yield: quantitative; ^1H NMR (600 MHz, $\text{CDCl}_3:\text{CD}_3\text{OD} = 1:1$, reference peak CD_3OD at 0.00 ppm) δ 4.85 (d, $J = 3.6$ Hz, 1H), 4.00–3.96 (m, 2H), 3.91 (dd, $J = 2.4, 1.2$ Hz, 1H), 3.86 (dd, $J = 10.8, 3.6$ Hz, 1H), 3.83 (t, $J = 6.6$ Hz, 1H), 3.80–3.76 (m, 2H), 3.75–3.72 (m, 2H), 3.69 (dd, $J = 10.2, 5.4$ Hz, 1H), 3.63 (td, $J = 8.1, 3.0$ Hz, 1H), 2.39 (dd, $J = 14.4, 3.0$ Hz, 1H), 2.30 (dd, $J = 14.4, 9.0$ Hz, 1H), 1.56–1.46 (m, 5H), 1.27 (bs, 46H), 1.16 (q, $J = 7.2$ Hz, 2H), 0.88 (dd, $J = 14.4, 6.6$ Hz, 9H); ^{13}C NMR (125 MHz, $\text{CDCl}_3:\text{CD}_3\text{OD} = 1:1$, reference peak CD_3OD at 49.0 ppm) δ 173.5, 100.2, 71.4, 70.7, 70.2, 69.6, 69.2, 67.8, 62.1, 54.2, 44.2, 39.6, 37.8, 34.5, 32.4, 30.9, 30.4, 30.2, 29.8, 28.4, 27.9, 26.3, 26.1, 23.1, 22.8, 14.3; LRMS(ESI) m/z for $\text{C}_{42}\text{H}_{83}\text{NaNO}_9$ [$\text{M} + \text{Na}$] $^+$ calcd: 768.60, found: 768.65.

Synthesis of SB2208, (3R)-3-hydroxy-N-((2S,3R)-3-hydroxy-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)nonadecan-2-yl)-14-methylhexadecanamide




Yield: quantitative; ^1H NMR (600 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1, v/v), reference peak TMS at 0.00 ppm): δ 4.85 (d, $J = 3.0$ Hz, 1H), 4.00–3.96 (m, 2H), 3.93–3.92 (m, 1H), 3.87–3.68 (m, 7H), 3.64–3.61 (m, 1H), 2.40–2.37 (m, 1H), 2.32–2.28 (m, 1H), 1.55–1.43 (m, 7H), 1.36–1.27 (m, 44H), 1.17–1.11 (m, 2H), 0.90–0.84 (m, 9H); ^{13}C NMR (150 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1, v/v), reference peak CD_3OD at 49.00 ppm): δ 173.5, 100.2, 71.5, 70.7, 70.2, 69.9, 69.2, 62.1, 54.2, 44.2, 37.8, 37.1, 34.9, 34.5, 32.4, 30.5, 30.2, 30.1, 30.0, 29.8, 27.6, 26.3, 26.1, 23.1, 19.4, 14.3, 11.6; LRMS(ESI) m/z for $\text{C}_{42}\text{H}_{83}\text{NaNO}_9$ [$\text{M} + \text{Na}$] $^+$ calcd: 768.60, found: 768.65.

Synthesis of SB2209, (R)-3-hydroxy-N-((2S,3R)-3-hydroxy-15-methyl-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexadecan-2-yl)hexadecanamide



Yield: quantitative; ^1H NMR (600 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1, v/v), reference peak TMS at 0.00 ppm): δ 4.85 (d, $J = 3.6$ Hz, 1H), 4.00–3.96 (m, 2H), 3.93–3.92 (m, 1H), 3.87–3.68 (m, 7H), 3.64–3.61 (m, 1H), 2.40–2.28 (m, 2H), 1.56–1.40 (m, 7H), 1.35–1.27 (m, 38H), 1.18–1.14 (m, 2H), 0.90–0.86 (m, 9H); ^{13}C NMR (150 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1, v/v), reference peak CD_3OD at 49.00 ppm): δ 173.7, 100.4, 78.5, 78.3, 78.1, 71.6, 70.9, 70.4, 69.8, 69.3, 62.3, 54.4, 44.4, 39.7, 38.0, 34.6, 32.6, 30.6, 30.4, 30.3, 30.0, 28.6, 28.1, 26.5, 26.2, 23.3, 23.0, 14.4; LRMS(ESI) m/z for $\text{C}_{39}\text{H}_{77}\text{NaNO}_9$ [$\text{M} + \text{Na}$] $^+$ calcd: 726.55, found: 726.60.


Synthesis of SB2210, (R)-3-hydroxy-N-((2S,3R)-3-hydroxy-15-methyl-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexadecan-2-yl)pentadecanamide



Yield: quantitative; ^1H NMR (600 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1, v/v), reference peak TMS at 0.00 ppm): δ 4.85 (d, $J = 3.6$ Hz, 1H), 4.00–3.96 (m, 2H), 3.93–3.92 (m, 1H), 3.87–3.68 (m, 7H), 3.63 (t, $J = 6.9$ Hz, 1H), 2.40–2.37 (m, 1H), 2.32–2.28 (m, 1H), 1.55–1.41 (m, 5H), 1.35–1.27 (m, 38H), 1.18–1.14 (m, 2H), 0.90–0.86 (m, 9H); ^{13}C NMR

(150 MHz, CD₃OD/CDCl₃ (1:1, v/v), reference peak CD₃OD at 49.00 ppm): δ 173.6, 100.3, 71.5, 71.4, 70.8, 70.3, 69.7, 69.2, 67.9, 62.2, 54.3, 44.3, 39.6, 37.9, 34.5, 32.5, 30.5, 30.3, 30.2, 30.2, 30.2, 29.9, 28.5, 28.0, 26.4, 26.1, 23.2, 22.9, 14.3; LRMS(ESI) m/z for C₃₈H₇₅NaNO₉ [M + Na]⁺ calcd: 712.53, found: 712.60.


Synthesis of SB2211, (R)-3-hydroxy-*N*-((2S,3R)-3-hydroxy-15-methyl-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexadecan-2-yl)-15-methylhexadecanamide



Yield: quantitative; ¹H NMR (600 MHz, CDCl₃:CD₃OD = 1:1, reference peak CD₃OD at 0.00 ppm) δ 4.85 (d, J = 3.0 Hz, 1H), 4.00–3.96 (m, 2H), 3.92 (d, J = 3.0 Hz, 1H), 3.86 (dd, J = 10.2, 2.4 Hz, 1H), 3.83 (t, J = 6.0 Hz, 1H), 3.80–3.76 (m, 2H), 3.75–3.72 (m, 2H), 3.71–3.68 (m, 1H), 3.62 (td, J = 7.8, 2.4 Hz, 1H), 2.38 (dd, J = 14.4, 3.6 Hz, 1H), 2.30 (dd, J = 14.4, 8.4 Hz, 1H), 1.56–1.46 (m, 6H),

1.28 (bs, 36H), 1.16 (q, J = 6.6 Hz, 4H), 0.87 (d, J = 6.6 Hz, 12H); ¹³C NMR (125 MHz, CDCl₃:CD₃OD = 1:1, reference peak CD₃OD at 49.0 ppm) δ 173.6, 100.3, 71.6, 71.4, 70.8, 70.3, 69.7, 69.2, 67.9, 62.2, 54.3, 44.3, 39.7, 37.9, 32.5, 30.5, 30.3, 30.3, 30.2, 30.2, 28.5, 28.0, 26.4, 26.2, 22.9; LRMS(ESI) m/z for C₄₀H₇₉NaNO₉ [M + Na]⁺ calcd: 740.56, found: 740.60.


Synthesis of SB2212, (3R)-3-hydroxy-*N*-((2S,3R)-3-hydroxy-15-methyl-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexadecan-2-yl)-14-methylhexadecanamide



Yield: quantitative; ¹H NMR (600 MHz, CDCl₃:CD₃OD = 1:1, reference peak CD₃OD at 0.00 ppm) δ 4.85 (d, J = 3.0 Hz, 1H), 4.00–3.96 (m, 2H), 3.92 (dd, J = 2.7, 1.8 Hz, 1H), 3.86 (dd, J = 10.2, 3.0 Hz, 1H), 3.83 (t, J = 6.0 Hz, 1H), 3.80–3.76 (m, 2H), 3.75–3.72 (m, 2H), 3.71–3.68 (m, 1H), 3.63 (td, J = 7.8, 2.4 Hz, 1H), 2.38 (dd, J = 13.8, 3.6 Hz, 1H), 2.30 (dd, J = 14.4, 8.4 Hz, 1H), 1.56–1.44 (m, 6H), 1.27 (bs, 36H), 1.16

(q, J = 7.2 Hz, 4H), 0.90–0.84 (m, 12H); ¹³C NMR (150 MHz, CDCl₃:CD₃OD = 1:1, reference peak CD₃OD at 49.0 ppm) δ 173.5, 100.2, 71.5, 70.7, 70.2, 69.6, 69.2, 62.2, 54.3, 44.2, 39.6, 37.8, 37.2, 35.0, 34.5, 30.5, 30.4, 30.2, 30.2, 30.0, 28.5, 27.9, 27.6, 26.4, 26.1, 23.1, 22.8, 19.4, 11.6; LRMS(ESI) m/z for C₄₀H₇₉NaNO₉ [M + Na]⁺ calcd: 740.56, found: 740.60.


Synthesis of SB2213, (3R)-3-hydroxy-*N*-((2S,3R)-3-hydroxy-14-methyl-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexadecan-2-yl)hexadecanamide



Yield: quantitative; ¹H NMR (600 MHz, CD₃OD/CDCl₃ (1:1, v/v), reference peak TMS at 0.00 ppm): δ 4.85–4.83 (m, 1H), 3.99–3.96 (m, 2H), 3.93–3.92 (m, 1H), 3.87–3.68 (m, 6H), 3.62 (m, 1H), 2.40–2.28 (m, 2H), 1.55–1.41 (m, 6H), 1.37–1.27 (m, 38H), 1.15–1.14 (m, 2H), 0.90–0.84 (m, 9H); ¹³C NMR (150 MHz, CD₃OD/CDCl₃ (1:1, v/v), reference

peak CD₃OD at 49.00 ppm); δ 173.7, 100.4, 71.6, 70.9, 70.4, 69.8, 69.3, 62.3, 54.4, 44.4, 38.0, 37.3, 35.1, 34.6, 32.6, 30.7, 30.4, 30.3, 30.3, 30.1, 30.0, 27.8, 26.5, 26.2, 23.3, 19.6, 14.4, 11.7; LRMS(ESI) m/z for C₃₉H₇₇NaNO₉ [M + Na]⁺ calcd: 726.55, found: 726.60.


Synthesis of SB2214, (3R)-3-hydroxy-N-((2S,3R)-3-hydroxy-14-methyl-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexadecan-2-yl)pentadecanamide



Yield: quantitative; ^1H NMR (600 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1, v/v), reference peak TMS at 0.00 ppm): δ 4.85 (d, $J = 3.6$ Hz, 1H), 4.00–3.96 (m, 2H), 3.93–3.92 (m, 1H), 3.87–3.68 (m, 7H), 3.63 (t, $J = 6.9$ Hz, 1H), 2.40–2.37 (m, 1H), 2.32–2.28 (m, 1H), 1.55–1.43 (m, 7H), 1.36–1.28 (m, 36H), 1.15–1.08 (m, 2H), 0.93–0.84 (m, 9H); ^{13}C NMR (150 MHz,

$\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1, v/v), reference peak CD_3OD at 49.00 ppm): δ 173.6, 100.3, 71.6, 71.4, 70.8, 70.3, 69.7, 69.2, 67.9, 62.2, 54.3, 44.3, 37.9, 37.2, 35.0, 34.5, 32.5, 30.6, 30.3, 30.3, 30.2, 30.2, 30.0, 29.9, 27.7, 26.4, 26.2, 23.2, 19.5, 14.3, 11.6; LRMS(ESI) m/z for $\text{C}_{38}\text{H}_{75}\text{NaNO}_9$ [$\text{M} + \text{Na}$] $^+$ calcd: 712.53, found: 712.60.


Synthesis of SB2215, (3R)-3-hydroxy-N-((2S,3R)-3-hydroxy-14-methyl-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexadecan-2-yl)-15-methylhexadecanamide



Yield: quantitative; ^1H NMR (600 MHz, $\text{CDCl}_3:\text{CD}_3\text{OD} = 1:1$, reference peak CD_3OD at 0.00 ppm) δ 4.85 (d, $J = 3.0$ Hz, 1H), 4.01–3.96 (m, 2H), 3.93 (d, $J = 1.8$ Hz, 1H), 3.86 (dd, $J = 10.2, 2.4$ Hz, 1H), 3.83 (t, $J = 6.0$ Hz, 1H), 3.78–3.72 (m, 4H), 3.71–3.68 (m, 1H), 3.63 (td, $J = 8.1, 2.4$ Hz, 1H), 2.39 (dd, $J = 14.4, 3.6$ Hz, 1H), 2.30 (dd, $J = 14.4, 9.0$ Hz, 1H),

1.56–1.43 (m, 6H), 1.28 (bs, 36H), 1.18–1.11 (m, 4H), 1.88–1.84 (m, 12H); ^{13}C NMR (125 MHz, $\text{CDCl}_3:\text{CD}_3\text{OD} = 1:1$, reference peak CD_3OD at 49.0 ppm) δ 173.5, 100.2, 71.5, 70.7, 70.2, 69.6, 69.2, 62.1, 54.2, 39.6, 37.8, 37.2, 34.9, 37.8, 37.2, 34.9, 30.5, 30.4, 30.2, 30.1, 30.0, 28.5, 27.9, 27.6, 26.4, 26.1, 22.8, 19.4, 11.6; LRMS(ESI) m/z for $\text{C}_{40}\text{H}_{79}\text{NaNO}_9$ [$\text{M} + \text{Na}$] $^+$ calcd: 740.56, found: 740.60.


Synthesis of SB2216, (3R)-3-hydroxy-N-((2S,3R)-3-hydroxy-14-methyl-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexadecan-2-yl)-14-methylhexadecanamide



Yield: quantitative; ^1H NMR (600 MHz, $\text{CDCl}_3:\text{CD}_3\text{OD} = 1:1$, reference peak CD_3OD at 0.00 ppm) δ 4.85 (d, $J = 3.0$ Hz, 1H), 4.00–3.96 (m, 2H), 3.92 (dd, $J = 3.0, 1.2$ Hz, 1H), 3.86 (dd, $J = 10.2, 3.0$ Hz, 1H), 3.83 (t, $J = 6.0$ Hz, 1H), 3.80–3.76 (m, 2H), 3.75–3.72 (m, 2H), 3.71–3.68 (m, 1H), 3.63 (td, $J = 7.8, 2.4$ Hz, 1H), 2.38 (dd, $J = 13.8, 3.6$ Hz, 1H), 2.30 (dd, $J = 14.4, 9.0$ Hz,

1H), 1.55–1.51 (m, 2H), 1.50–1.44 (m, 4H), 1.27 (bs, 36H), 1.17–1.08 (m, 4H), 0.90–0.84 (m, 12H); ^{13}C NMR (150 MHz, $\text{CDCl}_3:\text{CD}_3\text{OD} = 1:1$, reference peak CD_3OD at 49.0 ppm) δ 173.5, 100.2, 71.5, 70.7, 70.2, 69.6, 69.2, 62.1, 54.3, 44.2, 37.8, 37.2, 34.9, 34.5, 32.4, 30.5, 30.2, 30.2, 30.1, 27.6, 26.4, 26.1, 23.1, 19.4, 11.6; LRMS(ESI) m/z for $\text{C}_{40}\text{H}_{79}\text{NaNO}_9$ [$\text{M} + \text{Na}$] $^+$ calcd: 740.56, found: 740.60.


Synthesis of SB2217, (R)-3-hydroxy-N-((2S,3R)-3-hydroxy-15-methyl-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexadecan-2-yl)heptadecanamide



Yield: 98%; ^1H NMR (400 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1, v/v), reference peak TMS at 0.00 ppm): δ 4.85 (d, $J = 3.2$ Hz, 1H), 4.00–3.95 (m, 2H), 3.93–3.92 (m, 1H), 3.88–3.67 (m, 7H), 3.64–3.60 (m, 1H), 2.41–2.36 (m, 1H), 2.32–2.26 (m, 1H), 1.57–1.41 (m, 5H), 1.33–1.27 (m, 42H), 1.18–1.13 (m, 2H), 0.90–0.86 (m, 9H); ^{13}C NMR (100 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1,

v/v), reference peak CD_3OD at 49.00 ppm): δ 173.5, 100.3, 71.5, 71.4, 70.8, 70.3, 69.7, 69.2, 67.9, 62.2, 54.3, 44.3, 39.6, 37.9, 34.5, 32.5, 30.5, 30.2, 30.2, 29.9, 28.5, 28.0, 26.4, 26.1, 23.2, 22.9, 14.3; LRMS(ESI) m/z for $\text{C}_{40}\text{H}_{79}\text{NaNO}_9$ $[\text{M} + \text{Na}]^+$ calcd: 740.56, found: 740.60.


Synthesis of SB2218, (3R)-3-hydroxy-N-((2S,3R)-3-hydroxy-14-methyl-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexadecan-2-yl)heptadecanamide



Yield: quantitative; ^1H NMR (500 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1, v/v), reference peak TMS at 0.00 ppm): δ 4.85–4.84 (m, 1H), 3.99–3.60 (m, 12H), 2.40–2.27 (m, 2H), 1.55–1.39 (m, 6H), 1.36–1.23 (m, 37H), 1.17–1.07 (m, 3H), 0.94–0.80 (m, 9H); ^{13}C NMR (150 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1, v/v), reference peak CD_3OD at 49.00 ppm): δ 173.5, 100.2, 71.5, 71.3, 70.7, 70.2,

69.6, 69.2, 67.8, 62.1, 54.3, 44.2, 37.8, 37.2, 35.0, 34.5, 32.4, 30.5, 30.2, 30.2, 30.2, 30.0, 29.9, 27.6, 26.4, 26.1, 23.1, 19.4, 14.3, 11.6; LRMS(ESI) m/z for $\text{C}_{40}\text{H}_{79}\text{NaNO}_9$ $[\text{M} + \text{Na}]^+$ calcd: 740.56, found: 740.60.


Synthesis of SB2219, (R)-3-hydroxy-N-((2S,3R)-3-hydroxy-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)heptadecan-2-yl)heptadecanamide



Yield: quantitative; ^1H NMR (500 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1, v/v), reference peak TMS at 0.00 ppm): δ 4.85 (d, $J = 3.6$ Hz, 1H), 3.99–3.97 (m, 2H), 3.96–3.92 (m, 1H), 3.87–3.68 (m, 7H), 3.63–3.61 (m, 1H), 2.40–2.27 (m, 2H), 1.55–1.39 (m, 7H), 1.35–1.27 (m, 49H), 0.90–0.85 (m, 6H); ^{13}C NMR (100 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1, v/v), reference peak CD_3OD at 49.00 ppm):

δ 173.5, 100.2, 71.5, 71.3, 70.7, 70.2, 69.6, 69.2, 67.8, 62.1, 54.3, 44.2, 37.8, 34.5, 32.4, 32.4, 30.2, 30.2, 29.9, 26.3, 26.1, 23.1, 14.3; LRMS(ESI) m/z for $\text{C}_{40}\text{H}_{79}\text{NaNO}_9$ $[\text{M} + \text{Na}]^+$ calcd: 740.56, found: 740.60.


Synthesis of SB2220, (R)-3-hydroxy-N-((2S,3R)-3-hydroxy-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)heptadecan-2-yl)-15-methylhexadecanamide



Yield: quantitative; ^1H NMR (400 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1, v/v), reference peak TMS at 0.00 ppm): δ 4.87 (d, $J = 3.6$ Hz, 1H), 3.97 (m, 2H), 3.92 (m, 1H), 3.87–3.67 (m, 7H), 3.64–3.60 (m, 1H), 2.40–2.26 (m, 2H), 1.63–1.40 (m, 4H), 1.27 (m, 43H), 1.16–1.13 (m, 2H), 0.94–0.86 (m, 9H); ^{13}C NMR (100 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1, v/v), reference peak CD_3OD at

49.00 ppm): δ 173.5, 100.2, 71.5, 71.3, 70.7, 70.2, 69.6, 69.2, 62.1, 54.3, 44.2, 39.6, 37.8, 34.5, 30.4, 30.2, 30.2, 29.9, 28.5, 27.9, 26.3, 26.1, 23.2, 22.9, 14.3; LRMS(ESI) m/z for $\text{C}_{40}\text{H}_{79}\text{NaNO}_9$ $[\text{M} + \text{Na}]^+$ calcd: 740.56, found: 740.60.


Synthesis of SB2221, (3R)-3-hydroxy-N-((2S,3R)-3-hydroxy-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)heptadecan-2-yl)-14-methylhexadecanamide



Yield: quantitative; ^1H NMR (400 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1, v/v), reference peak TMS at 0.00 ppm): δ 4.87–4.83 (m, 1H), 3.97 (m, 2H), 3.92 (m, 1H), 3.87–3.68 (m, 7H), 3.64–3.60 (m, 1H), 2.40–2.20 (m, 2H), 1.61–1.40 (m, 5H), 1.27 (m, 38H), 1.18–1.09 (m, 2H), 0.90–0.84 (m, 9H); ^{13}C NMR (100 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1, v/v), reference peak CD_3OD at 49.00

ppm); δ 172.8, 99.5, 70.8, 70.6, 70.0, 69.5, 68.9, 68.4, 61.4, 53.5, 43.5, 37.1, 36.4, 34.2, 33.7, 31.7, 29.8, 29.5, 29.4, 29.3, 29.1, 26.9, 25.6, 25.4, 22.4, 18.7, 13.5, 10.9; LRMS(ESI) m/z for $\text{C}_{40}\text{H}_{79}\text{NaNO}_9$ $[\text{M} + \text{Na}]^+$ calcd: 740.56, found: 740.60.


Synthesis of SB2222, (3R)-3-hydroxy-N-((2S,3R)-3-hydroxy-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)heptadecan-2-yl)-14-methylhexadecanamide



Yield: 74%; ^1H NMR (500 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1, v/v), reference peak TMS at 0.00 ppm): δ 4.87 (d, J = 3.75 Hz, 1H), 3.97–3.90 (m, 2H), 3.82–3.70 (m, 7H), 3.63–3.59 (m, 1H), 2.23 (t, J = 7.55 Hz, 2H), 1.63–1.48 (m, 5H), 1.43–1.27 (m, 44H), 1.18–1.14 (m, 2H), 0.90–0.86 (m, 9H); ^{13}C NMR (150 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1,

v/v), reference peak CD_3OD at 49.00 ppm); δ 175.43, 100.52, 71.49, 71.36, 70.82, 70.34, 69.66, 68.20, 62.26, 54.48, 39.63, 36.96, 34.51, 32.47, 30.49, 30.27, 30.26, 30.23, 30.20, 30.19, 30.14, 29.99, 29.89, 28.51, 27.97, 26.54, 26.29, 23.18, 22.90, 14.31; LRMS(ESI) m/z for $\text{C}_{40}\text{H}_{79}\text{NaNO}_8$ $[\text{M} + \text{Na}]^+$ calcd: 724.57, found: 724.45.



Synthesis of SB2223, (3R)-3-hydroxy-N-((2S,3R)-3-hydroxy-1-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)heptadecan-2-yl)-14-methylhexadecanamide







Yield: 83%; ^1H NMR (500 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1, v/v), reference peak TMS at 0.00 ppm): δ 4.85 (d, J = 3.5 Hz, 1H), 3.99–3.95 (m, 2H), 3.92 (m, 1H), 3.87–3.67 (m, 7H), 3.64–3.61 (m, 1H), 2.40–2.36 (m, 1H), 2.32–2.27 (m, 1H), 1.55–1.41 (m, 6H), 1.32–1.27 (m, 44H), 0.89 (t, J = 7.0 Hz, 6H); ^{13}C NMR (150 MHz,

$\text{CD}_3\text{OD}/\text{CDCl}_3$ (1:1, v/v), reference peak CD_3OD at 49.00 ppm); δ 173.53, 100.26, 71.54, 71.43, 70.79, 70.26, 69.68, 69.20, 67.91, 62.18, 54.29, 44.26, 37.84, 34.51, 32.47, 30.24, 30.22, 30.19, 29.89, 26.40, 26.13, 23.18, 14.30; LRMS(ESI) m/z for $\text{C}_{39}\text{H}_{77}\text{NaNO}_9$ $[\text{M} + \text{Na}]^+$ calcd: 726.55, found: 726.45.

2. ¹H and ¹³C NMR spectra









7.271
7.253
7.249
7.127
7.111
7.016
6.895
6.889
6.872
6.836
6.820
6.814
6.797
6.783
4.444
4.434
4.398
4.385
3.897
3.859
3.850
3.837
3.829
3.821
3.808
3.795
3.771
3.760
3.740
3.722
3.610
3.603
3.591
3.584
3.578
3.560
3.555
3.066
3.060
3.052
3.036
2.784
2.775
2.766
2.747
2.738
2.523
2.517
2.508
1.917
1.902
1.888
1.879
1.865
1.797
1.786
1.773
1.761
1.756
1.745
1.257
-0.000

SHM_11_40_41_CDCl3_proton_20150410_500MHz

Sample Name:
SHM_11_40_41_CDCl3_proton_20150410_500MHz
Data Collected on:
smu500-wmrs500
Archive directory:
Sample directory:
FidFile: PROTON
Pulse Sequence: PROTON (s2ps1)
Solvent: cdcl3
Data collected on: Apr 10 2015





SHM_11_40_41_CDCl3_carbon_20150410_500MHz 159.415



130.587
130.306
130.200
130.055
129.485
127.176
114.050
114.019
113.890
113.814
110.487

77.488
77.230
76.979
73.032
72.968
71.016
67.271
66.937
66.869
55.694
55.482
55.428
50.301
47.300
35.138
33.163


Sample Name:
SHM_11_40_41_CDCl3_carbon_20150410_500MHz
Data Collected on:
smu500-wmrs500
Archive directory:
Sample directory:
FidFile: CARBON
Pulse Sequence: CARBON (s2ps1)
Solvent: cdcl3
Data collected on: Apr 10 2015




SHB_11_42_CDCl3_proton_20150413_300MHz_exp1




S9






SHB_11_42_CDCl3_carbon_20150413_300MHz_exp5





S9







7.258
7.237
6.882
6.861
SHB_11_100_CDCl3_proton_21050615_400MHz





159.453
134.239
132.979
130.269
129.510
129.495
126.041
125.351
114.026
99.044
77.250
76.911
73.162
73.124
71.758
71.333
70.839
69.220
68.987
68.835
67.894
67.864
62.551
55.462
40.935
37.663
36.548
36.016
35.462
32.836
30.984
29.952
29.929
29.883
29.785
29.739
29.679
29.603
29.565
29.512
29.443
29.314
27.599
26.430
26.392
25.800
25.701
19.903
SHB_11_100_CDCl3_carbon_21050615_400MHz









SHB_13_72_CDC13_1H_20160108_300MHz_exp2




S13(n16)







SHB_13_72_CDC13_13C_20160108_300MHz_exp3




S13(n16)









HYS-1-46-HN300-CDC13-20160107_exp1




HYS-1-46-CN300-CDC13-20160107_exp2




SHB_14_74_CDC13_1H_20160415_300MHz_exp1



SHB_14_74_CDC13_13C_20160415_300MHz_exp2





SHB_15_9C_CDCl3_1H_20160905_300MHz_exp1




SHB_15_9C_CDCl3_13C_20160905_300MHz_exp2










SHB_14_64_CDCl3_1H_20160404_300MHz_exp3




SHB_14_64_CDCl3_13C_20160404_300MHz_exp4













SHB_13_100_CDC13_1H_20160129_300MHz_exp4



SHB_14_5_CDC13_1H_20160205_300MHz_exp2




SHB_14_5_CDC13_13C_20160205_300MHz_exp3




SHB_14_6_CDC13_1H_20160210_300MHz_exp1

7.357
7.335
7.315
7.309
7.300
7.289
7.278
7.268
7.257
7.248
5.081
5.051
4.936
4.898
4.856
4.847
4.824
4.785
4.756
4.735
4.722
4.696
4.684
4.662
4.641
4.601
4.562
4.524
4.503
4.464
4.418
4.399
4.375
4.358
4.117
4.106
4.028
4.016
3.995
3.983
3.971
3.922
3.902
3.876
3.866
3.841
3.832
3.768
3.752
3.498
3.476
2.190
2.186
2.167




S23(a17)





SHB_14_6_CDC13_13C_20160210_300MHz_exp2

135.74
135.06
134.89
134.82
134.73
134.57
128.54
128.51
128.51
128.40
128.28
128.00
128.00
127.96
127.96
127.96
127.62
98.72
88.77
79.65
79.65
77.56
77.43
77.23
77.23
75.94
75.18
74.98
74.98
73.30
73.30
70.68
69.66
69.00
69.00
67.89
53.88
36.85
36.51
36.51
29.92
29.83
29.19
29.19
29.21
28.90
28.90
29.31
19.44
18.97
11.63
0.21



S23(a17)







SHB_15_7C_CDC13_13C_20160830_300MHz_exp2





SHB_14_35Ab_HPLC_CDC13_1H_20160315_300MHz_exp1

7.270
7.267
7.258
7.253
7.247
7.241
7.228
7.217
7.202
5.291
5.082
5.053
4.954
4.936
4.916
4.898
4.856
4.846
4.825
4.813
4.786
4.757
4.735
4.723
4.696
4.684
4.662
4.642
4.623
4.602
4.563
4.524
4.503
4.463
4.418
4.397
4.373
4.357
4.156
4.132
4.118
4.109
4.085
4.028
4.016
3.994
3.962
3.969
3.922
3.898
3.874
3.865
3.856
3.840
3.831





SHB_14_35Ab_HPLC_CDC13_13C_20160315_300MHz_exp2

155.74
139.08
138.81
138.21
138.13
138.13
128.55
128.51
128.46
128.10
128.07
128.01
127.74
127.61
98.71
88.78
79.42
77.65
77.44
77.23
75.15
74.98
73.68
70.27
69.64
69.13
67.90
53.87
32.14
29.99
29.57
29.37
28.61
28.61
22.91
18.56
18.35
0.21



SHB_14_35Bb_pro_HPLC_CDCl3_1H_20160316_300MHz_expl




7.349
7.333
7.304
7.283
7.256
7.231
7.205
7.180
7.167
6.619
6.602
5.466
5.445
5.430
5.359
5.337
4.903
4.879
4.821
4.795
4.713
4.696
4.626
4.598
4.575
4.531
4.507
4.485
4.456
4.433
4.409
4.381
4.357
3.994
3.974
3.864
3.840
3.798
3.759
3.469
2.344
2.315
2.300
2.275
2.261
2.110
2.096
2.082
1.977
1.963
1.949
1.466
1.453
1.438
1.422
1.408
1.334
1.294
1.280
1.246
0.978
0.863
0.845
0.000

KSH-2-58A_spot1_2
H_CDC13_2016-04-14


Sample Name:
SHB_14_75C_CDC13_1H_20150420_500MHz
Data Collected on:
snu500-vnars500
Archive directory:

Sample directory:

FidFile: PROTON
Pulse Sequence: PROTON (s2pu1)
Solvent: cdcl3
Data collected on: Apr 20 2016




S24(n18/n16)






SHB_14_75C_CDC13_13C_20160420_300MHz_exp5



171.19
139.08
138.87
138.64
138.19
138.00
128.52
128.52
128.44
128.44
128.39
128.20
128.13
128.01
127.98
127.78
127.69
124.60
96.79
89.05
87.65
77.43
77.23
75.83
75.06
74.94
73.46
73.17
71.67
69.75
69.04
68.73
68.73
52.51
41.73
35.03
31.92
29.90
29.87
29.57
29.57
29.37
28.61
27.67
22.90
18.39
14.33







S24(n18/n16)



























SHB_14_75A_CDCl3_1H_20160420_300MHz_exp2




S24(17/n16)





SHB_14_75A_CDCl3_13C_20160420_300MHz_exp1




S24(17/n16)




SHB_14_69A_CDCl3_1H_20160420_300MHz_exp6




S24(i17/m15)



SHB_14_69A_CDCl3_13C_20160420_300MHz_exp7



S24(i17/m15)




SHB_13_97_CDCl3_1H_20160129_500MHz


7.254
7.233
7.207
7.181
6.616
6.599
5.444
5.359
4.903
4.880
4.820
4.737
4.714
4.697
4.662
4.626
4.600
4.576
4.554
4.531
4.507
4.484
4.456
4.433
4.409
4.381
4.357
3.993
3.973
3.862
3.840
3.796
3.759
3.727
3.697
3.232
2.314
2.275
2.246
2.173
2.095
2.043
2.021
1.963
1.611
1.535
1.504
1.439
1.423
1.393
1.241
1.144
1.041
0.988
0.972
0.955
0.863
0.000


Sample Name: KDN-2-31A benzylation_H_CDCl3_2016-01-28
 Data Collected on: wnu500-usar500
 Archive directory:
 Sample directory:
 FidFile: PROTON

Pulse Sequence: PROTON (s2pul)
 Solvent: cdcl3
 Data collected on: Jan 29 2016




SHB_13_97_CDCl3_13C_20160129_300MHz_exp3







SHB_14_66A_CDC13_13C_20160502_300MHz_exp1











7.349
7.333
7.319
7.304
7.283
7.269
7.256
7.243
7.219
7.205
7.180
6.624
6.607
4.903
4.880
4.822
4.736
4.713
4.696
4.643
4.624
4.599
4.576
4.551
4.508
4.485
4.456
4.434
4.409
4.382
4.358
3.988
3.975
3.864
3.841
3.793
3.765
3.470
2.338
2.316
2.202
2.276
2.111
2.097
2.064
1.991
1.978
1.964
1.950
1.455
1.440
1.425
1.294
1.248
1.125
1.112
1.097
1.072
0.891
0.879
0.862
0.847
0.828
-0.000



Sample Name: SHB_14_75B_CDC13_1H_20150420_500MHz
Data Collected On: smu500-vvmsa500
Archive directory:
Sample directory:
FidFile: PROTON
Pulse Sequence: PROTON (s2pul)
Solvent: cdcl3
Data collected on: Apr 20 2016




SHB_14_75B_CDC13_13C_20160420_300MHz_exp4


















SHB_14_66B_CDC13_13C_overnight_20160504_300MHz_exp1































D:\Data\NMR&MALDI\p.1\NICEM_NMR\SHB051016\SHB_14_89_CDCl3_MeOD_cosolv_MeOD_shim_1H_20160509_600MHz_NICEM.esp






















D:\Data\NMR&MALDI\p.1\NICEM_NMR\SHB051016\3\SHB_14_87_CDCI3_MeOD_cosolv_MeOD_shim_1H_20160509_600MHz_NICEM.esp

